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DEVELOPMENT OF BIOANALYTICAL METHODS FOR QUANTITATIVE 
MEASUREMENT OF ANTICANCER AGENTS
SANDEEP REDDY KUNATI
ABSTRACT
The ever-growing need to develop new anticancer agents due to increased
incidence of cancer and its recurrence has led to a broad range of investigational efforts
in anticancer research. Drug discovery and development processes involve evaluations of
pharmacokinetic and pharmacodynamic parameters of potential drug candidates in order
to assess their safety, toxicity, and efficacy profiles. By providing sensitivity, assay
precision, reliability, and high-throughput, mass spectrometry has become an
indispensable tool in quantitative and qualitative analysis, from early-stage drug
discovery and development processes to routine laboratory analysis. Development of
bioanalytical methods requires knowledge of separation science with instrumentation,
data interpretation and sample preparation techniques from complex biological matrices.
This work describes the theory, instrumentation, and method development processes
behind these investigations. Further, detailed method development and validation
procedures for investigational anticancer agents MLN0128, GS87, and curcumin using
liquid chromatography-tandem mass spectrometry were presented.
v
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CHAPTER I
INTRODUCTION TO BIOANALYTICAL METHOD DEVELOPMENT
1.1 General introduction
The increased worldwide incidence of cancer and its recurrence combined with 
severe side-effects associated with chemotherapy and increased drug resistance 
necessitates constant research and development for new and efficient anticancer agents. 
Historically, drug candidates were isolated from natural products or discovered through 
serendipitous discovery; however, recent advances in medicine enabled us to target 
specific entities at molecular and physiological levels by understanding the biochemical 
mechanisms of disease progression. Potential drug candidates screening involves 
assessment of pharmacokinetic and pharmacodynamic parameters in preclinical studies to 
assess safety profiles, followed by clinical trials to assess safety, efficacy, effectiveness 
and adverse effects [1].
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Pharmacokinetics (PK) is the study of the movement of the drug in the body 
through the processes of absorption (A), distribution (D), metabolism (M), and excretion 
(E) and refers to the concentration of the drug at a certain time point [2]. 
Pharmacodynamics (PD) is the study of the effects of the drug on the body and refers to 
the concentration of the drug at the site of action in regards to time and resulting 
physiological and biochemical effects [3].
Quantitative analysis of drug molecules provide ADME parameters and 
concentration-time profiles which are used to determine bioavailability, dosage regimen, 
and therapeutic range to assess pharmacological and toxicological effects and are integral
to the clinical investigations [4]. The methods used for the quantitation must show proven
selectivity, accuracy, precision, and robustness for the measurement of drug molecules
concentration in biological matrices. In addition, they need to be cost-effective, less labor
intense, and enable high throughput.
Bioanalysis involves extraction of the analyte of interest from the biological 
matrix, its detection followed by the quantitation. As bioanalysis requires measurement 
of very low concentration of analyte in biological matrix, traditional detection techniques 
such as HPLC-DAD/FLD suffer from limited sensitivity at such concentrations, whereas, 
mass spectrometry overcomes these issues by providing selectivity and specificity for the 
analyte. The advancement of LC-MS combined with sample preparation techniques made 
it an initial method of choice in bioanalysis without the requirement of sample volatility 
and involvement of derivatization processes for polar, thermally labile samples as in GC- 
MS. Tandem mass spectrometry (LC-MS/MS) allows high-throughput assays with a high
2
degree of sensitivity measuring analytes at nanogram to picogram levels with a small 
amount of the sample matrix and overcomes the matrix interference issues that may arise 
due to the presence of endogenous or exogenous compounds that coexist with the analyte.
1.2 High-Performance Liquid Chromatography (HPLC)
High-performance liquid chromatography is one of the widely used analytical 
techniques for qualitative and quantitative analysis of chemical species due to its broad 
applicability and assay precision [5]. HPLC separates components of a mixture based on 
their affinities towards the mobile phase and/or the stationary phase. The sample is 
partitioned between the mobile and stationary phases inside the column and based on its 
physicochemical properties, either it is strongly retained or eluted out of the column 
affecting the retention time. By altering the stationary phase chemistry and/or 
composition of the mobile phase components, the elution profile of the analyte can be
altered.
Sample characteristics such as polarity, charge, functional groups, and molecular 
size determine the separation mode. Reversed-phase chromatography (RPC or RP-HPLC) 
uses nonpolar stationary phase and a mixture of water and miscible organic solvents and 
mainly used to separate neutral or nonionized compounds that are soluble in its mobile 
phase solvents. Normal-phase chromatography (NPC) uses polar stationary phase and 
mixture of non-polar organic solvents and mainly used for the separation of water- 
insoluble compounds. Hydrophilic interaction chromatography (HILIC) is used to
3
separate highly polar analytes using polar stationary phase and a mixture of water and an 
organic solvent as mobile phase. Ion-exchange chromatography (IEC) separates ionizable 
samples using resin with charged groups that bind to sample ions of opposite charge 
using an aqueous solution of a salt with buffer. Size-exclusion chromatography (SEC) 
separates compounds based on their molecular size using an inert column with aqueous 
or organic mobile phase [6]. RPC is the most widely used separation mode today and 
current work exclusively deals with the RPC.
The main components of HPLC system are shown in Figure 1.1. It consists of a 
solvent reservoir for the mobile phase, a pumping system to transfer the mobile phase 
into the column, an autosampler to introduce the sample into the mobile phase without 
interrupting the flow, an analytical column for the separation of the sample components 
and a detector for the signal detection.
4
Figure 1.1. Components of HPLC.
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1.2.1 Mobile phase
In RPC, mobile phase is composed of water, organic modifiers, and other 
additives (buffers, acid or base). Commonly used organic modifiers include methanol, 
acetonitrile, and tetrahydrofuran (THF) and selection of appropriate solvent depends on 
the analytes chemistry. Snyder's solvent-selectivity triangle (Figure 1.2) based on the
proportions of solvents acidity (α), basicity (β), and dipole character (π*) provides a good
approach for solvent selection [7]. For greater selectivity change, selection of solvents 
from different regions of the triangle is desired; however, it is important to consider 
solvent-strength selectivity before moving to a solvent with different properties as a 
varying percentage of organic modifier effectively changes the retention time of the 
analytes. Elution strength of the reversed-phase solvents increases in the order of water, 
methanol, acetonitrile and THF and polarity decreases in that order.
For ionizable compounds, changes in eluent pH alter the extent of ionization 
affecting polarity and hydrophobicity and thus the interaction between the analyte and the 
stationary phase. Controlling eluent pH optimizes the separation and stabilizes retention 
and selectivity. In conjunction with pH, pKa, acid dissociation constant, is used to predict 
the extent of ionization of a compound at particular pH. When pH and pKa are equal, 
ionized and unionized forms of the compound will be in equal concentrations in the 
solution. Altering the pH by 1 near the pKa greatly changes the ionization status. If pH is 
greater than pKa, basic compounds stay in unionized form while acidic compounds in 
ionized form. Compounds ionized and unionized forms give different retention 
characteristics, ionized forms are more polar and less retained under RP conditions,
6
whereas unionized forms are less polar and retained longer. Buffer solutions are 
commonly employed as an aqueous portion of the mobile phase due to their resistance to 
changes in the eluent pH. For LC-MS applications, the mobile phase must be volatile, so 
it is important to choose a volatile buffer to avoid the contamination of the source. Table 
1.1 lists some of the commonly used LC-MS mobile phase additives and buffers.
Partition-coefficient (LogP) and distribution-coefficient (LogD) are generally 
used to measure hydrophobicity or lipophilicity balance of the compounds. LogP refers 
to the logarithmic ratio of the concentrations of the unionized compound in aqueous 
phase to a non-polar solvent and independent of pH. A positive value indicates that the 
compound is more hydrophobic and zero value indicates that the compound is equally 
partitioned between aqueous and lipid phases. LogD refers to the logarithmic ratio of sum 
of the concentrations of solutes in ionized and unionized forms in one solvent to the other 
at given pH. LogP or LogD combined with pKa are used to understand the drug 
compounds physicochemical properties. Although these values can be measured 
experimentally, software such as ACDLabs can be used for their prediction [9].
7
Figure 1.2. Solvent-selectivity triangle. Reproduced with permission from reference [7]. 
Copyright (1993) Elsevier.
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Additive/buffer Structure pKa Buffer range
Trifluoroacetic acid CF3CO2H 0.5 3.8-5.8
Formic acid HCO2H 3.8 -
Ammonium formate HCO2NH4 3.8 2.8-4.8
Acetic acid CH3CO2H 4.8 -
Ammonium acetate CH3CO2NH4 4.8 3.8-5.8
4-Methylmorpholine OC4H8N(CH3) 8.4 7.4-9.4
Ammonium bicarbonate NH4CO3H 6.3/9.2/10.3 6.8-11.3
Ammonium acetate CH3CO2NH4 9.2 8.2-10.2
Ammonium formate HCO2NH4 9.2 8.2-10.2
1 -Methylpiperidine C5H10N(CH3) 10.1 10.0-12.0
Triethylammonium acetate CH3CO2NH(CH3)3 11.0 10.0-12.0
Pyrrolidine C4H8NH 11.3 10.3-12.3
Table 1.1. LC-MS buffers and mobile phase additives. Reproduced with permission from 
reference [8].
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1.2.2 Column
In RPC, column or stationary phase is normally packed with silica solid support 
material for adsorption and partition due to its higher surface area, mechanical strength 
and ability to bond with different ligands. Selection of column depends on the sample 
characteristics and the separation goals. The traditional approach involves measuring 
LogP or LogD of the analyte along with pKa to get an idea of hydrophobicity required 
for the analyte retention. Initial column screening often begins with choosing a column 
from a similar application and progresses to rigorous screening based on orthogonality. 
Column characterization approaches based on measuring retention capacity, 
hydrophobicity, steric resistance, hydrogen bond acidity and basicity, and silanol 
ionization at pH 2.8 (low) and 7.0 (high) provide means of understanding of column 
chemistries and thus help in the selection of similar or dissimilar columns to attain or 
alter selectivity [10-12]. Based on column characteristics, type and degree of interaction 
vary between the stationary phase surface and the analyte. Several databases are available 
for the column selection based on these approaches [13, 14].
In RPC, due to the analytes polar nature, they are solubilized in polar mobile 
phase and non-polar stationary phase is used for elution. Stationary phases such as C18, 
C8, cyano or phenyl are commonly used. Commonly encountered column-solute 
interactions in RPC are shown in Figure 1.3. Hydrophobic interactions are the primary 
mechanism of retention and occur between non-polar stationary phase and non-polar 
functional groups of analytes. Steric interactions are used to separate analytes based on 
steric influences such as size and shape. Hydrogen bond interactions between analytes
10
and stationary phase based on analytes donating and accepting capacity with counter 
groups on the stationary phase. Ion-exchange interactions take place between ionizable 
functional groups of analytes and counter-charged functional groups of solid support on 
the column. Charge-transfer interactions, π-π, and dipole-dipole, also contribute to the 
selectivity of aromatic and unsaturated compounds. π-π interactions primarily occur 
between an aromatic functional group of the column and the aromatic analyte. Dipole- 
dipole interactions take place between oppositely charged dipoles of analyte molecules
and the column ligand. Combination of these interactions may also be used for complex
mixtures.
The principal factors that cause band broadening and reduce column efficiency
are eddy diffusion, longitudinal diffusion, and mass transfer effects. Eddy diffusion
describes the analytes flow path variations due to the particle size variations of the
packing material and can be reduced by selecting well-packed columns with smaller
particle size dimensions. Longitudinal diffusion results from the analytes dispersion to
the outer edges of the band due to the concentration gradient and can be reduced by using
higher flow velocity and reducing internal volumes of the system. Mass transfer effects
result from the porous nature of the stationary phase and analyte molecules non-uniform
penetration inside the particle and can be reduced by reducing the particle size and the
linear velocity.
11
Figure 1.3. Analyte-column interactions in RPC. Reproduced with permission from
reference [15]. Copyright (2007) American Chemical Society.
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1.3 Mass Spectrometer
Mass spectrometer produces gas-phase ions from the chemical species and 
separates them according to their mass-to-charge ratios (m/z). The resultant mass 
spectrum provides quantitative and/or qualitative information of the sample components 
[16]. Mass spectrometer consists of an ion source, mass analyzer, and a detector (Figure
1.4).
13
Figure 1.4. Components of mass spectrometer.
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1.3.1 Ion source
Ion source converts the incoming sample components from hplc into gas-phase 
ions and accelerates them towards the mass analyzer. Based on the sample characteristics 
electrospray ionization (ESI), atmospheric pressure chemical ionization (APCI) and 
atmospheric pressure photoionization (APPI) techniques are commonly employed in LC- 
MS and referred as atmospheric pressure ionization (API) techniques. API occurs at 
atmospheric pressure conditions and are soft ionization techniques, producing little 
fragmentation and useful for molecular mass determination. API processes form pseudo­
molecular ions by the association or dissociation of protons due to the negligible amount 
of energy transferred to the ion.
Electrospray ionization is the most widely used ionization technique in LC-MS 
due to its wide range of applicability from small molecules to large biomolecules. It is 
suitable for the analysis of moderate to highly polar analytes and analytes with multiple 
charges. ESI involves three basic processes, droplet formation, desolvation and gas-phase 
ion formation (Figure 1.5). In ESI, analytes are ionized within the hplc eluent and 
transferred to the capillary tip held at atmospheric pressure. The droplets at the tip are 
conventionally shaped due to the surface tension of the eluent. Assuming positive ESI 
mode, application of high-voltage repels the cations within the droplet towards the 
surface increasing the charge density at the tip leading to the formation of a liquid cone, 
referred as Taylor cone and ejaculates a stream of droplets containing cations into the 
desolvation zone. As the solvent evaporates with the aid of drying gas and temperature, 
the droplets shrink and charges within the droplet repel each other reaching Rayleigh
15
instability limit followed by exceeding it, resulting in smaller stable droplet production, 
termed jet fission, and subsequently producing gas phase ions [17-19]. There are several 
factors that influence the ESI processes including capillary diameter, emitter to inlet 
distance, eluent flow rate, electrolyte concentration, solvent properties, applied potential, 
and temperature [20, 21].
The common chemical reactions in ESI include protonation and deprotonation 
resulting in [M+H] and [M-H]-. Protonation is often seen due to the wide range of basic 
analytes requiring acidic analyte solution. Adducts such as [M+Na]+, [M+K]+, and 
[M+NH4]+ may arise from the buffer solution used to control the pH of the mobile phase, 
laboratory glassware, analysts, or the sample itself. Sodium and potassium adducts are
more stable and may result in less further fragmentation. The adduct ion formation can be
controlled by keeping the concentration of buffer solution to a minimum and increasing
the proton concentration in the solution by lowering the pH using organic acids.
As ESI is the most versatile technique in bioanalysis, care should be taken to 
avoid ion suppression effects which may result from the non-volatile substances present 
in the sample or the mobile phase or from the analyte precipitation [22]. Ion suppression 
may also result from the mobile phase additives which have higher proton affinity than 
the analyte in the gas-phase [23].
16
Figure 1.5. Schematic of the ESI process. Reproduced from reference [24].
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1.3.2 Mass analyzer
Mass analyzer separates the incoming gas-phase ions according to their mass-to-
charge (m/z) ratios. Based on the application, different types of mass analyzers such as
quadrupoles, time-of-flight, ion traps, and magnetic sectors are used.
Quadrupole mass analyzer consists of two pairs of parallel equidistant rods
typically made of molybdenum due to its high inertness and arranged in a radial array.
The schematic of quadrupole mass analyzer is depicted in Figure 1.6. A combination of 
direct current (DC) and radio frequency (RF) voltages are used to separate ions according 
to their mass-to-charge ratios. One of the pairs on the axis contains an applied potential of 
+(U+Vcos(ωt)) and the other -(U+Vcos(ωt)), where U is magnitude of DC voltage, V is 
magnitude of RF voltage, ω is the angular frequency (2πf) of RF waveform and t is time. 
The potential applied on the x-axis is 180o out of phase with equal magnitude but 
opposite sign on the y-axis. The arrangement of rods produces a radius of r0 between x 
and y-axis. If the amplitude of the passing ion is within r0, it passes through the rods in a 
helical trajectory without collision, whereas, if the radius exceeds r0, the ion collides with 
the rods and eventually pumping into waste. By controlling the U and V parameters, ions 
with particular mass-to-charge ratios can be oscillated towards the stable trajectory. As 
compared to other mass analyzers, quantitative aspects of quadrupoles are quite complex 
and described using stability diagrams [25].
Quadrupole mass analyzers are widely used instruments due to their low cost,
rapid scanning over wide mass ranges, and good reproducibility, but suffer from low
resolution and mass discrimination.
18
In Time-of-flight (TOF) mass analyzer, incoming ions are subjected to an 
accelerating potential in an evacuated tube. The ions travel based on their mass and 
charge and by measuring the time taken for the ions to reach the detector their mass-to- 
charge ratios can be calculated. TOF mass analyzers provide unlimited mass range 
making them widely used instruments in the analysis of high molecular weight 
biomolecules.
In Ion trap mass analyzer, incoming ions are stored in the trap and manipulated by 
altering DC and RF voltage. Use of inert gas enables selected ion fragmentation within 
the trap and by altering the voltage, ions with specific mass-to-charge ratios can be
separated. Ion traps are very useful for structural elucidation as they provide mass
spectrum of all the ions.
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Figure 1.6. Quadrupole mass spectrometer.
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1.3.3 Ion detector
Once the ions exit the mass analyzer, they strike the surface of the detector where 
the incident ion signal generates current or electrons and further amplified. Commonly 
used ion detectors in mass analyzers include Faraday cup detector, electron multiplier, 
photomultiplier tube (PMT), and microchannel plate detector (MCP). Faraday cups detect 
the voltage drop resulted from the induced current produced by the incident ions striking 
the dynode and are used to determine the isotope abundance ratios [26]. In electron 
multiplier, incident ion strikes the first dynode resulting in the emission of secondary
electrons and the secondary electrons strike the second dynode and so on creating a 
cascade of electrons [27]. Electron multipliers are widely used detectors in ion detection 
systems. In PMT, incident ion strikes the photocathode emitting photons, which then 
strike the dynode releasing secondary electrons and so on releasing a cascade of electrons. 
MCP detectors comprised of an array of microchannels of continuous electron multipliers 
and work in a similar fashion as individual electron multipliers and spread over the final
electron cascade to four electrodes of anode providing a spatial resolution from their 
ratios [28].
1.3.4 Tandem mass spectrometry (MS/MS)
Tandem mass spectrometry refers to the combination of two or more mass 
analyzers in tandem and is used for structural elucidation and quantitative analysis with 
high selectivity. In triple-quadrupole mass spectrometer (QqQ), shown in Figure 1.7, the
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initial quadrupole (Q1) detects the precursor ions which are further fragmented in the 
collision cell (q2) producing product ions and are detected by the second quadrupole (Q3). 
Multiple-reaction-monitoring (MRM) mode is the widely used tandem mode for 
quantitation and structural confirmation. In MRM mode, Q1 allows precursor ions of 
specific mass-to-charge ratio and Q3 allows specific mass-to-charge ratio of product ions 
enabling the monitoring of the precursor ion and its dissociated ions sequentially with 
their ratios, thus providing specificity to the analyte(s).
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Figure 1.7. Schematic of triple-quadrupole mass spectrometer.
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1.4 Sample preparation
Biological samples such as plasma, serum, whole blood, urine, and tissues contain
complex matrices which need to be removed before mass spectrometric analysis,
otherwise, they contaminate both HPLC and MS systems reducing sensitivity and
affecting reproducibility. Sample preparation ensures that the analyte is separated from
the interfering matrix components and also increases the sensitivity of the analyte by
derivatization or preconcentration processes. The commonly employed sample 
preparation techniques in bioanalysis are protein precipitation, liquid-liquid extraction, 
and solid phase extraction. The selection of suitable sample preparation technique
depends on the analyte properties such as molecular size, solubility and functional group
chemistry and also the characteristics of the sample matrix. Developing an efficient
sample extraction method is important because insufficient sample clean up can lead to
matrix effects, ion suppression, and ion enhancement, compromising the validity of the
analysis.
1.4.1 Protein precipitation (PPT)
Protein precipitation is widely used sample preparation technique in bioanalysis to
remove proteins from the sample due to its simplicity, rapid sample clean-up process, and
applicability to small molecules irrespective of their polarity. As the drug binds to plasma
proteins in the systemic circulation, it is necessary to separate the analyte from the
plasma proteins before the analysis to warrant the recovery. Precipitation is achieved by
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the addition of organic solvents (acetonitrile, ethanol, methanol, acetone), acids 
(trichloroacetic acid, perchloric acid), salts (ammonium sulfate), or metal ions (Zn2+) to 
the sample [29, 30]. The resultant precipitate is separated by filtration and/or 
centrifugation. In aqueous solution, proteins are surrounded by water molecules forming 
an outer hydration layer preventing protein aggregation. Addition of organic solvent 
disrupts this hydration layer resulting in increased hydrophobicity and also lowers the 
dielectric constant of the solution thereby increasing the electrostatic forces between 
protein molecules causing protein aggregation. Addition of high concentration of salt also 
causes the similar effect due to salt ions interaction with the charges on the proteins [31,
32].
A typical protein precipitation protocol is shown in Figure 1.8. To plasma sample,
an internal standard working solution followed by 4 to10 volumes of organic solvent is 
added, vortex mixed and centrifuged. The resultant supernatant is dried under nitrogen 
flow, reconstituted with the mobile phase and injected into LC.
25
Figure 1.8. Typical protein precipitation protocol.
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1.4.2 Liquid-liquid extraction (LLE)
Liquid-liquid extraction is another widely used sample preparation technique in 
bioanalysis due to its simplicity, rapid method development process, and applicability to 
non-polar to moderately polar analytes. In LLE, to plasma sample, an internal standard 
working solution and an extraction buffer are added followed by the addition of an 
immiscible organic solvent. The mixture is agitated, centrifuged, and the organic layer is 
separated, dried under nitrogen flow, and reconstituted in the mobile phase.
In LLE, analyte and other sample components are separated by partitioning 
between the original sample solvent and an immiscible organic solvent based on their 
differential solubility. Agitation or shaking transfers the components between the phases 
and separates the two layers, and analyte or interferences get extracted into immiscible 
solvent from original sample solvent resulting in a cleaner sample. In LLE, an analyte in
unionized form provides greater recovery by preferential solubilization in an organic 
solvent, so pH adjustment may be required for polar analytes [33]. As bioanalysis 
samples are aqueous, a water-immiscible organic solvent such as ethyl acetate, methyl 
tertiary-butyl ether (MTBE), methylene chloride or hexane is commonly employed as 
extraction solvents. Selection of extraction solvent depends on the analyte solubility and 
polarity characteristics but also depends on its water immiscibility and volatility. As LLE 
is based on partition coefficient of the analyte between the two phases, it is necessary to 
know the analytes chemical properties such as pH, pKa, LogP, and LogD for efficient 
separation.
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The fraction of analyte extracted into organic phase is calculated using below 
formulas [34]. The concentration ratio of analyte between aqueous and organic phases
remains constant and described by the distribution constant, KD
After the partition of analyte from aqueous to organic phase, the fraction of analyte
extracted into organic phase is given by
Where Vorg is the volume of organic phase, Vaq is the volume of aqueous phase, and V 
the ratio Vorg/Vaq
For multiple extractions, the fraction of analyte is calculated by
Where n is number of extractions.
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1.4.3 Solid-phase extraction (SPE)
Solid-phase extraction is the most powerful sample preparation technique in terms
of selectivity, recovery, reproducibility, ease of automation, and its applicability to wide
range of compounds from non-polar to polar. SPE allows isolation of target analyte while
removing all other sample interferences resulting in cleaner extracts. SPE cartridges
contain solid sorbent material, which is selected based on the physical and chemical
properties of the analyte of interest or the impurities present in the sample. By altering the 
interaction between the adsorbent and sample components, the required component can 
be isolated and collected.
Typical SPE protocol is shown in Figure 1.9. In SPE, to plasma sample, an 
internal standard working solution is added and may be subjected to a pretreatment by 
adding buffer solution to adjust the pH for ionizable analytes. The SPE cartridges are 
conditioned with methanol to activate the sorbent, equilibrated using buffer solution to 
precondition the sorbent followed by loading the sample. Washing with suitable solvent 
elutes co-retained interferences and finally the analyte of interest is eluted from the 
adsorbent using methanol. The resultant solvent is dried under nitrogen flow and 
reconstituted in the mobile phase.
As SPE is another form of chromatography, analyte retention and elution follows
chromatographic principles.
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Figure 1.9. Typical solid-phase extraction protocol.
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1.5 Method development
The process of method development begins with the information of the sample
such as its composition and properties and defining the separation goals. Sample
characteristics such as sample matrix, expected concentration range, molecular weight,
solubility characteristics, LogP, LogD, pKa, and functional group chemistry plays an
important role in the method development process. Physicochemical properties of the
analyte help in the selection of suitable solvents, chromatography mode, and analytical 
column. If the compound is deemed to be suitable for mass spectrometric analysis, a 
suitable mode of ionization, and determination and optimization of precursor and product
ions is required. Although C18 column is the first choice in RPC analysis, selection of
stationary phase based on analytes hydrophobicity characteristics ensure the selectivity of
the method. Chromatographic parameters including mobile phase solvents, flow rate,
temperature, pH, and analytical column need to be evaluated for optimal selectivity. In
LC-MS method development process, optimization follows MS, LC, and sample
preparation procedure followed by the final method optimization for sensitivity and
specificity. The optimized method is validated according to the guidelines set forth by the
US-FDA for bioanalytical method validation.
1.6 Method validation
Analytical method validation demonstrates that the developed method is suitable
for the intended purpose and ensures reliability. The US Food and drug administration
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has developed a validation protocol as guidance for industry for bioanalytical method 
validation and is outlined in Table 1.2 [35]. The validation in the order of selectivity, 
matrix effects, stability, linearity, accuracy, precision and long-term stability are 
suggested [36]. If required selectivity and matrix effects are not achieved, the sample 
preparation method should be revised. Evaluation of stability before accuracy and 
precision studies ensures that the sample is stable under the experimental conditions. For 
endogenous analytes, due to the presence of the analyte in the control matrix several
alternatives were presented in the literature as a replacement for control matrix including
the use of control matrix with low concentration of the analyte, an addition of a stable
isotope analogue of the analyte to the control matrix, standard addition technique where
analyte is spiked into control matrix above the endogenous concentration, use of
surrogate matrix where endogenous analytes are removed from the control matrix, or use
of the sample solvent [37].
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Parameter Experimental Acceptance criteria; 
CV (%) and RE (%)
Selectivity All peaks need to be resolved from one 
another in the chromatogram.
LLOQ To prove selectivity of the method, LLOQ 
needs to be measured in at least six matrix 
lots (n=5).
≤20%
Matrix
Effects
Matrix effects across six matrix lots need to 
be evaluated using internal standard.
If deuterated internal standard used, one 
matrix lot need to be evaluated (n=5).
≤15%
Recovery Evaluated at three concentrations in the 
matrix.
≤15%
Calibration Blank, zero and six to eight non-zero 
calibrators, including LLOQ in the matrix.
≤15% ;
At LLOQ ≤20%
At least 67% of non­
zero standards should 
meet the criteria, 
including LLOQ and 
ULOQ
Accuracy
and
Precision
Intra-assay, inter-assay and dilution studies 
at three concentrations in the matrix (n≥5).
≤15%
Stability Stock solution stability at room 
temperature for at least 6 hours.
Short-term stability based on expected 
duration of the sample at room temperature 
(4 - 24hours).
Post-preparative stability based on sample 
resident time in the autosampler. 
Freeze-and-thaw, three cycles, at sample 
storage conditions).
Long-term storage conditions.
(n=3 at two concentrations)
≤15%
Table 1.2. FDA bioanalytical method validation guidelines.
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1.7 Conclusion
The quantification of drug molecules in biological matrices for clinical
investigations requires careful consideration of instrumentation along with sample
extraction techniques. Bioanalytical method development requires knowledge of
separation science, instrumental parameters, and sample preparation procedures to ensure
selectivity and accuracy of the method. In this chapter, an overview of the theory and 
instrumentation of HPLC and MS, sample extraction techniques from the complex 
biological matrices, method development scheme and validation guidelines set forth by 
the US Food and Drug Administration for bioanalytical method validation were presented.
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CHAPTER II
DETERMINATION OF MLN0128, AN INVESTIGATIONAL
ANTINEOPLASTIC AGENT, IN HUMAN PLASMA BY LC-MS/MS
2.1 Introduction
MLN0128 (also known as INK128) is a potent, small-molecule anticancer agent 
developed by Millennium Pharmaceuticals. MLN0128 is an orally active and highly 
selective inhibitor of mTOR (mammalian target of rapamycin) kinase which has two 
distinct multi-protein complexes, TORC1 and TORC2 (TORC1/2), for regulating critical 
aspects of cell survival, proliferation, and metastasis [1, 2]. TORC1/2 are upregulated in 
some tumors and play important roles in the PI3K/Akt/mTOR signaling pathway which is 
often dysregulated in human tumorigenesis [3-6]. The mechanism of MLN0128 for 
treatment of cancer is that the agent competes with ATP for binding to and inhibiting 
TORC1/2 active sites, which may result in tumor cell death and halt tumor cell growth 
[7].
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MLN0128 has shown activity against a large number of human tumor cell lines 
with diverse tissue origins and genetic makeups including acute lymphoblastic leukemia, 
renal cell carcinoma, prostate, breast, endometrial, and lung cancers and demonstrated 
inhibitory activity toward mTOR signaling in human tumor xenograft mouse models with
well-defined pharmacological properties [8-13]. Up to date, two Phase I clinical trials of 
MLN0128 were conducted, which showed acceptable safety profiles [14-15]. These 
findings warrant further clinical trials of MLN0128 in patients with various advanced and
recurrent cancers [16].
Since there is no published analytical method available for pharmacological study 
of MLN0128 in human based on the recent Scifinder® database search and the needs of 
such method for clinical studies are present and real; therefore, we have developed a 
liquid chromatography-tandem mass spectrometry method in this work for quantitative 
determination of MLN0128 in human plasma to support the clinical development of the 
drug. The method developed has been validated according to the US Food and Drug 
Administration guidance for industry on bioanalytical method validation [17] with the 
intention to be used for pharmacokinetic study of MLN0128 in clinical trials.
2.2 Experimental
2.2.1 Chemicals
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MLN0128 {3-(2-aminobenzo[d]oxazol-5-yl)-1-isopropyl-1H-pyrazolo [3,4-d]
pyrimidin-4-amine, C15H15N7O} was purchased from Selleckchem (Houston, TX, USA) 
(Catalog no. S2811, purity >99.64%). STK040263 {1-benzyl-1H-pyrazolo [3,4- 
d]pyrimidin-4-amine, C12H11N5} (as internal standard, IS, purity >90%) was purchased 
from Vitas-M Laboratory (Apeldoorn, Netherlands). (Figure 2.1). LC/MS-grade 
methanol (MeOH), LC/MS-grade acetonitrile (ACN), HPLC-grade water, HPLC-grade 
methyl tert-butyl ether (MTBE), and ACS-grade dimethylsulfoxide (DMSO) were 
purchased from Fisher Scientific (Pittsburgh, PA, USA). Ammonium formate was from 
Sigma-Aldrich (St. Louis, MO, USA). Blank pooled human plasma and six individual 
lots of blank human plasma with specific lot numbers (IR11-1670, 1M2070-01, 1M2070- 
02, 1M2070-03, 1M2070-04, 1M2070-05, and 1M2070-06) were purchased from 
Innovative Research (Novi, MI, USA).
2.2.2 Instrumentation
The liquid chromatography-tandem mass spectrometry (LC-MS/MS) system used 
in this work consisted of a Shimadzu (Columbia, MD, USA) Prominence UFLC unit with 
a controller (CBM-20A), two binary pumps (LC-20AD) and an autosampler (SIL- 20AC), 
and an AB Sciex (Foster City, CA, USA) API3200 turbo-ion-spray® triple quadrupole 
tandem mass spectrometer equipped with an electrospray ionization (ESI) probe and a 
syringe pump. The LC-MS/MS system was controlled by AB Sciex Analyst® (version 
1.5.1) software for its operation, data acquisition, and processing.
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STK040263 (internal standard), MW = 225
Figure 2.1. Structures of MLN0128 and IS.
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2.2.2.1 Liquid Chromatography
Chromatographic separation of MLN0128 and the IS was carried out isocratically 
at room temperature on a Waters (Milford, MA, USA) XTerra® MS C18 column (2.1 mm 
× 50 mm, 3.5 μm) connected to a Waters XTerra® MS C18 guard column (2.1 mm × 10 
mm, 3.5 μm) with mobile phase consisting of methanol/acetonitrile/ammonium formate 
(10.0 mM, pH 2.8) (34:6:60, v/v/v) pumped at a flow rate of 0.300 mL min-1. ACN was 
used as the wash solvent between injections. For each analysis, 10.0 μL of sample was 
injected into the system by autosampler set at 4oC, and the total run time was 4 min.
2.2.2.2 Tandem mass spectrometry
Mass spectrometric detection was carried out using positive electrospray 
ionization (ESI+) mode, which was tuned for compound-dependent and source-dependent 
parameters by separate infusion of MLN0128 (500 ng mL-1) and IS (500 ng mL-1) in the 
mobile phase by the syringe pump at a flow rate of 10.0 μL min-1. The optimized 
parameters were as follows: curtain gas at 45 psi; collision gas at 3 psi; ion spray voltage 
at 5500 V; temperature at 600 oC; ion source gas 1 at 55 psi; ion source gas 2 at 45 psi; 
declustering potential at 60 V; entrance potential at 7.5 V; collision energy at 35 eV; 
collision cell exit potential at 4 V; and resolution at 0.7 units. Quantitation of MLN0128 
and IS was done in multiple-reaction-monitoring (MRM) mode with the mass transitions, 
m/z 310 > 268 for MLN0128, and m/z 226 > 127 for the IS, respectively, using a dwell
time of 400 ms for each analyte.
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2.2.3 Preparation of stock and working solutions
The stock solutions of MLN0128 (1.00 mg mL-1) and IS (1.00 mg mL-1) were 
prepared individually by dissolving an appropriate amount of compound in a known 
volume of DMSO. These stock solutions were kept in a freezer at -20oC before use. The
working solutions of MLN0128 (1.00 μg mL-1) and the IS (1.00 μg mL-1) were freshly 
prepared by serial dilution of each stock solution with the mobile phase.
The stock solution of ammonium formate (0.100 M) was prepared by dissolving 
an appropriate amount of ammonium formate salt in a known volume of HPLC-grade 
water and stored in a refrigerator at 4oC before use. The working solution of ammonium 
formate (10.0 mM) was prepared by a 10-fold dilution of the stock solution with HPLC- 
grade water and adjusted to pH 2.8 using formic acid, if necessary.
2.2.4 Preparation of standard solutions
The standard solutions of MLN0128 (1.00, 2.00, 2.50, 5.00, 10.0, 25.0, 30.0, 50.0, 
100, 200, 250, 300, 400 and 500 ng mL-1) were prepared daily by sequential dilution of 
the working solution with the mobile phase to make higher concentrations of the standard 
solutions (e.g., 100, 200, 250, 300, 400 and 500 ng mL-1) and by serial dilutions of these 
standard solutions with the mobile phase to make lower concentrations of the standard 
solutions (e.g., 1.00, 2.00, 2.50, 5.00, 10.0, 25.0, 30.0, 50.0 ng mL-1). The standard 
solution of the IS at concentration of 50 ng mL-1 was prepared freshly by direct dilution 
of working solution of the IS with the mobile phase.
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2.2.5 Preparation of plasma calibrators and quality controls
Plasma MLN0128 calibrators (0.100, 0.200, 0.500, 1.00, 2.50, 5.00, 10.0, 25.0 
and 50.0 ng mL-1) were prepared by mixing 10.0 μL of each MLN0128 standard solution 
(1.00, 2.00, 5.00, 10.0, 25.0, 50.0, 100, 250, and 500 ng mL-1) with 90.0 μL of blank 
pooled human plasma. The zero calibrator (or single blank plasma) was prepared by 
mixing 10.0 μL of the mobile phase with 90.0 μL of blank pooled human plasma. Plasma 
MLN0128 quality controls (QCs) (0.25, 3.00, 40.0 ng mL-1) were prepared by mixing 
10.0 μL of each MLN0128 standard solution (2.50, 30.0, and 400 ng mL-1) with 90.0 μL 
of blank pooled human plasma. The plasma MLN0128 calibrators and QCs were stored at 
-20oC before use.
2.2.6 Plasma sample preparation
Plasma samples (e.g., calibrator and QC) were thawed to room temperature and 
placed in disposable borosilicate glass tubes (13 x 100 mm) from VWR (Radnor, PA, 
USA). For each 100 μL of plasma sample, 10.0 μL of the IS (50.0 ng mL-1) were added 
except the double blank plasma where 10.0 μL of the mobile phase were added. After 
vortexing for 30 s, 2 mL of MTBE were added to the sample tube, and the liquid phases 
were mixed in a multi-tube vortex mixer (Troemner, Thorofare, NJ, USA) for 5 min to 
extract the analytes, then centrifuged in a Sorvall ST40R centrifuge (Thermo Scientific, 
Waltham, MA, USA) at 4816 x g at 4oC for 8 min. The organic phase (upper layer) was 
transferred into a fresh borosilicate glass tube and dried in a TurboVap® LV evaporator
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(Caliper Life Sciences, Hopkinton, MA, USA) at 30oC under nitrogen gas at a pressure of 
20 psi for 12 min. The resultant dried residue was reconstituted in 100 μL of a 
reconstitution solution containing methanol and 10 mM ammonium formate (pH 2.8) (1:9,
v/v) for the subsequent LC-MS/MS analysis.
2.2.7 Method validation
The method developed was validated in human plasma following the US-FDA 
guidance for industry on bioanalytical method validation in terms of selectivity, lower 
limit of quantitation, matrix effect, recovery, linear calibration range, accuracy, and 
precision, as well as stabilities for short-term sample processing and long-term sample
storage.
2.2.7.1 Selectivity and lower limit of quantitation (LLOQ)
The selectivity of this method was assessed by any interferents observed at the 
retention times and mass transitions of MLN0128 and the IS in six individual blank 
human plasma and blank pooled human plasma matrices. The LLOQ of the method was 
defined as the lowest concentration of MLN0128 plasma calibrator with accuracy 
expressed as percent relative error (%RE) and precision expressed as percent coefficient
of variation (%CV) at ≤ ±20% and ≤ 20%, which was validated in six individual and
pooled human plasma matrices.
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2.2.7.2 Matrix factor (MF) and recovery
The absolute MF of MLN0128 (or the IS) was determined by the mean peak area 
of MLN0128 (or the IS) at a specified concentration in the extracted plasma matrix over 
that of MLN0128 (or the IS) at the concentration in the reconstitution solution. The IS 
normalized MF was determined by the absolute MF of MLN0128 over that of the IS. For 
this study, MLN0128 QCs at three concentrations (0.250, 3.00 and 40.0 ng mL-1) with a 
fixed concentration of the IS (5.00 ng mL-1) were prepared in six individual extracted 
plasma matrices and in the reconstitution solution.
The absolute recovery of MLN0128 (or the IS) was determined by the mean peak 
area of MLN0128 (or the IS) at a specific concentration in plasma matrix over that of 
MLN0128 (or the IS) at the concentration in the extracted plasma matrix multiplying by 
100%. The IS normalized recovery was determined by the absolute recovery of 
MLN0128 over that of the IS multiplying by 100%. For this study, MLN0128 QCs at 
three concentrations (0.250, 3.00 and 40.0 ng mL-1) with a fixed concentration of the IS 
(5.00 ng mL-1) were prepared in the pooled and the extracted pooled human plasma 
matrices.
2.2.7.3 Linear calibration curve
MLN0128 calibration curve was constructed using nine non-zero plasma 
calibrators, one single-blank (with the IS only), and one double-blank plasma (without 
MLN0128 or the IS). The concentrations of non-zero calibrators were 0.100, 0.200, 0.500,
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1.00, 2.50, 5.00, 10.0, 25.0 and 50.0 ng mL-1 with the IS concentration of 5.00 ng mL-1. 
The peak area ratios of MLN0128 to the IS (y) were plotted versus the concentrations of 
MLN0128 plasma calibrators (x) with 1/x weighting.
2.2.7.4 Accuracy, precision, and dilution study
In this work, the intra-assay accuracy and precision were determined using five 
replicate injections of QC samples at three different concentrations (0.250, 3.00 and 40.0 
ng mL-1). The inter-assay accuracy and precision were determined using five parallel 
injections from five identical QCs at three different concentrations (0.250, 3.00 and 40.0 
ng mL-1) in three separate days. Dilution study was conducted using QC concentration at 
250 ng mL-1 which was 5 times beyond the upper limit of the linear calibration curve (50 
ng mL-1), and the analysis was carried out after 10-fold dilution of plasma dilution QC by 
the pooled blank human plasma.
2.2.7.5 Stability
The stabilities of the MLN0128 stock solution (1.00 mg mL-1) and plasma QCs 
(0.250 and 40.0 ng mL-1) were investigated against test controls at the same 
concentrations prepared fresh on the day of the experiment. The stability of MLN0128 
was determined from five replicates by comparing the mean-peak-area ratio of MLN0128 
to the IS in a test sample to that of the test control and multiplying by 100%.
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In the stability studies, the stock solution was kept on bench top (23oC) for 6 and 
24 h before dilution to 1.00 and 50.0 ng mL-1. The QCs were kept on bench top (23oC) 
before sample preparation or in an autosampler (4oC) after sample preparation for 6 and 
24 h. For the freeze-and-thaw study, the QCs were subjected to three freeze-and-thaw 
cycles where the samples were frozen at -20oC for at least 24 h and thawed at room 
temperature (23oC) unassisted. For long-term storage study, the QCs were stored at - 
20oC and tested up to two months. For the above studies, the working solution of the IS 
(50.0 ng mL-1) was prepared fresh on the day of the experiment and added to each sample 
prior to sample extraction.
2.3 Results and discussion
2.3.1 Method development
2.3.1.1 Internal standard (IS)
Due to the lack of a heavy stable isotope of MLN0128, several commercially 
available structural analogs such as PP2 (Sigma Aldrich, MO, USA), STK040263 and 
STK560245 (Vitas-M Laboratory, Apeldoorn, Netherlands) were acquired and evaluated 
as an IS for quantitation of MLN0128. STK040263 was chosen for the subsequent work
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because it was rapidly and efficiently separated from MLN0128 by isocratic elution, 
whereas the other structural analogs needed gradient elution to achieve the similar result.
2.3.1.2 Chemical properties of the analyte and the IS
Both MLN0128 and STK040263 are small, weak basic, organic molecules with
monoisotopic masses of 309 and 225 g/mol (Figure 2.1). The LogP and pKa (of 
conjugate acid) of these compounds calculated by the ACDLabs® software version 11.02 
(Advanced Chemistry Development, Inc., Toronto, Ontario, Canada) are 2.35 and 3.77 
for MLN0128, and 1.36 and 4.20 for STK040263, respectively. The LogP values reveal
hydrophobic nature of these compounds, whereas the pKa values of the conjugate acids 
suggest the amino groups of these compounds are protonated at low pH values. These 
chemical properties of the analyte and the IS had guided us in the selections of solvent, 
mobile phase, and chromatographic column.
2.3.1.3 Mass spectrometric detection
In this work, triple quadrupole tandem mass spectrometer (MS/MS) was used for 
analyte detection due to its high selectivity and low limit of detection. Since MLN0128 
and the IS were readily protonated in the acidic mobile phase (pH 2.8), positive 
electrospray ionization (ESI+) was chosen as a means of sample introduction. As shown 
in Figure 2.1, MLN0128 and the IS readily produced protonated molecules
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[MLN0128+H]+ at m/z 310 (Figure 2.2A) and [IS+H]+ at m/z 226 (Figure 2.2B) in the 
ionization chamber of the mass spectrometer, and these precursor ions were further 
fragmented in the collision cell into predominant product ions at m/z 268 for MLN0128
and at m/z 127 for the IS. These predominant product ions were further confirmed using 
Agilent 6540 UHD Accurate-Mass Q-TOF LC/MS system (Agilent Technologies, Santa 
Clara, CA, USA) (Figure 2.3), and the chemical structures of these ions were postulated 
with the aid of Agilent Molecular Formula Generator and Molecular Structure 
Coordinator software. In the case of product ion of the IS (m/z 127), there was no 
structure suggested by the software, the postulated structure was hypothesized based on 
the chemical structure of the precursor ion and the found fragment formula (C10H7+) of 
the product ion. Multiple reaction monitoring (MRM) mode was adopted for quantitation 
of MLN0128 with the mass transitions of m/z 310 > 268 for MLN0128 and m/z 226 >
127 for the IS, respectively.
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Figure 2.2. The mass spectra of precursor and product ions of MLN0128 and IS.
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Figure 2.3. The mass spectra of product ions of MLN0128 and IS using Q-TOF.
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2.3.1.4 Liquid chromatographic separation
Due to the hydrophobic nature of MLN0128 and STK040263, reversed-phase 
chromatographic columns were considered for analytical separation. Several columns 
including Waters MS® XTerra C18, Waters MS XTerra® C8, and Waters Atlantis® T3 
(Waters Corporation, Milford, MA, USA) were tested. Among them, Waters XTerra® 
MS C18 column was chosen because it exhibited more symmetrical and sharper peaks 
with improved resolution and signal-to-noise ratio in comparison to the others.
Because both MLN0128 and STK040263 are amine derivatives, they have 
tendency to adsorb on the silica solid support. The use of ammonium formate (10.0 mM 
at pH 2.8) as a component of the mobile phase not only promotes the formation of 
protonated analytes but also dynamically compete with the analyte and the IS to prevent 
the chemical tailing on the column [18, 19]. Furthermore, for achieving a proper solvent
strength and selectivity, a mixture of methanol and acetonitrile at a ratio of 85/15 (v/v) 
was used as another component of the mobile phase for rapid and efficient separation of 
the analyte and the IS.
For this work, the optimized liquid chromatographic separation was obtained 
using a Waters XTerra® MS C18 column, and a mobile phase consisting 60% of 
ammonium formate (10.0 mM, pH 2.8) and 40% methanol/acetonitrile (85/15, v/v) 
pumped at a flow rate of 0.300 mL min-1. The total run time was 4.00 min with retention 
times of 1.95 and 2.94 min for the IS and MLN0128, respectively.
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2.3.1.5 Plasma sample preparation
Both protein precipitation and liquid-liquid extraction (LLE) were investigated as 
plasma sample preparation methods in this work. Even though protein precipitation was 
simpler to do, but it gave a lower analyte recovery and stronger matrix effect in 
comparison to LLE.
For the LLE study, several organic solvents such as MTBE, ethyl acetate, 
isopropanol, and hexane were investigated as extraction solvents for plasma sample either 
alone or in combination. While MTBE showed the highest extraction efficiency, hexane 
yielded none. Therefore, MTBE was chosen as the organic solvent for the sample 
preparation by LLE. Figure 2.4 shows the matrix effect of the MTBE-extracted blank 
plasma injected by the autosampler on the analytical signal of analyte standard solution 
(i.e., the baseline signal) via post-column infusion, which revealed that the matrix effect 
(i.e., signal elevation or suppression) mainly occurred in the retention times between 0.80 
min and 1.50 min, and did not affect the analytical signals of the IS and MLN0128 at the 
peak values of 1.95 min and 2.94 min, respectively.
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Figure 2.4. The mass chromatograms of post-column infusion of MLN0128 (A) injection 
of 10.0 μL mobile phase; and (B) injection of 10.0 μL MTBE-extract of blank human
plasma.
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2.3.1.6 Reconstitution solution
During plasma sample preparation, MTBE-extract containing the analyte and the 
IS was dried under nitrogen gas, and the resultant residue was reconstituted in a 
reconstitution solution for the subsequent LC-MS/MS analysis. For this work, the mobile 
phase was initially used as the reconstitution solution to reconstitute the dried residue; 
however, it produced a cloudy solution (colloidal suspension) and caused injection 
problem. In an attempt to remove the cloudiness of the reconstitute, various ratio of 
acetonitrile/methanol as the organic components of the mobile phase, and various buffer 
compositions (e.g., ammonium formate, ammonium acetate or ammonium bicarbonate) 
and concentrations (e.g., 5.00 to 20.0 mM) as the aqueous component of the mobile phase 
were tested, which showed no change on the cloudiness of the reconstitute. Eventually, 
the use of lower percentage of organic solvent in reconstitution solution [i.e., 10% MeOH 
with 90% ammonium formate solution (10.0 mM, pH 2.8)] resulted in clear sample 
solution. Therefore, 10% MeOH with 90% ammonium formate solution (10.0 mM, pH
2.8) was chosen as the reconstitution solution of the subsequent work.
2.3.2 Method validation
2.3.2.1 Selectivity and Lower limit of quantitation
The selectivity and the LLOQ of the method were examined in this work. As
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illustrated by the representative mass chromatograms of the double blank plasma (Figure 
2.5A) recorded at the same mass transitions of MLN0128 and the IS, while no detectable 
interference was observed at the same retention time of IS, a tiny endogenous interferent 
peak was detected near the retention time of MLN0128. The representative mass 
chromatograms of the single blank plasma (Figure 2.5B) showed that the interferent was 
not a part of the IS. Since the mean peak area of the endogenous interferent from six 
different individual double blank plasmas was less than 6% of that of MLN0128 at the 
LLOQ (Figure 2.5C), which was much lower than the limit set by US-FDA (≤ 20%); 
therefore, the interferent was tolerated at the LLOQ in this method. The LLOQ of this 
method was 0.100 ng mL-1 for MLN0128, which had the accuracy and precision ≤ ±9% 
and ≤ 7% (Table 2.1) assessed by five replicate measurements of six plasma calibrators at 
LLOQ each prepared by a different individual blank plasma.
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Figure 2.5. The mass chromatograms of MLN0128 and IS in human plasma (A) double 
blank plasma (with neither MLN0128 nor IS); (B) single blank plasma (with IS only at 
50.0 ng mL-1); and (C) at LLOQ (MLN0128 at 0.100 ng mL-1 and IS at 50.0 ng mL-1).
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Plasma
matrix
[Nominal] 
(ng mL-1)
[Measured] 
(ng mL-1)
SD
(ng mL-1)
Precision
(CV%)a
Accuracy
(RE%)b
Lot 1 0.100 0.104 0.001 1 4
Lot 2 0.100 0.101 0.004 4 1
Lot 3 0.100 0.093 0.003 3 -7
Lot 4 0.100 0.102 0.007 7 2
Lot 5 0.100 0.096 0.003 3 -4
Lot 6 0.100 0.109 0.003 3 9
a %CV = (Standard deviation/mean) x 100%.
b %RE = [(measured - nominal)∕(nominal)] x 100%.
Table 2.1. Accuracy and precision of MLN0128 at LLOQ in six individual lots of human 
plasma (n = 5).
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2.3.2.2 Matrix effect and recovery
Matrix effect was assessed by the matrix factor (MF) of MLN0128 at three QC 
concentrations in six individual plasma matrices. As shown in Table 2.2, the absolute 
MFs of MLN0128 and the IS ranged 0.93-0.1.04 and 0.91-1.03, respectively; and the IS 
normalized MFs ranged 0.96-1.08. These data revealed that the matrix effect of human 
plasma was negligible in the measurements of MLN0128 and the IS when MTBE was 
used as organic solvent for the analyte extraction.
The recoveries of MLN0128 at three different QC concentrations in pooled 
human plasma were summarized in Table 2.3. The absolute recoveries of MLN0128 and 
the IS ranged 79-84% and 81-84%, respectively; and the IS normalized recoveries ranged 
95-100%. These results indicated that MTBE extraction used was efficient and consistent 
for the recovery of MLN0128 and the IS from human plasma samples.
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Plasma
matrix
[MLN0128] 
(ng mL-1)
MFMLN0128
± SDa
MFIS 
± SDb
IS Normalized MF 
± SDc
Lot 1 0.250 1.02±0.02 0.94±0.02 1.08±0.04
3.00 1.02±0.03 0.95±0.01 1.07±0.02
40.0 0.99±0.02 0.96±0.01 1.04±0.02
Lot 2 0.250 0.96±0.03 0.91±0.02 1.05±0.05
3.00 1.00±0.02 0.98±0.01 1.02±0.03
40.0 0.98±0.01 0.98±0.01 1.00±0.02
Lot 3 0.250 0.98±0.06 1.00±0.01 0.98±0.05
3.00 0.99±0.01 0.98±0.01 1.01±0.02
40.0 0.93±0.01 0.97±0.01 0.96±0.01
Lot 4 0.250 1.04±0.06 1.02±0.01 1.01±0.06
3.00 1.01±0.01 1.00±0.01 1.01±0.01
40.0 0.96±0.01 0.95±0.02 1.01±0.01
Lot 5 0.250 0.99±0.04 0.99±0.00 1.00±0.04
3.00 0.99±0.01 0.97±0.02 1.02±0.01
40.0 0.97±0.01 0.95±0.01 1.02±0.02
Lot 6 0.250 1.0±0.1 1.03±0.01 1.0±0.1
3.00 0.98±0.02 0.96±0.03 1.02±0.02
40.0 0.94±0.02 0.92±0.03 1.02±0.02
a MFMLN0128 = (mean peak area of MLN0128 in the extracted plasma matrix)/(mean peak area of 
MLN0128 in the reconstitution solution).
b MFIS = (mean peak area of the IS in the extracted plasma matrix)/(mean peak area of the IS in the 
reconstitution solution).
c IS normalized MF = MFMLN0128/MFIS.
Table 2.2. Matrix factors of MLN0128 in six individual lots of human plasma (n = 5).
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[MLN0128] 
(ng mL-1)
RecoveryMLN0128a 
± SD (%)
RecoveryISb
± SD (%)
IS Normalized Recoveryc 
± SD (%)
0.250 84 ± 3 84 ± 1 100 ± 3
3.00 80 ± 2 84 ± 3 95 ± 3
40.0 79 ± 1 81 ± 2 98 ± 1
a RecoveryMLN0128 = [(mean peak area of MLN0128 in plasma matrix)/(mean peak area of MLN0128 in 
extracted plasma matrix)] x100%.
b RecoveryIS = [(mean peak area of IS in plasma matrix)/( mean peak area of IS in extracted plasma 
matrix)] x 100%.
c IS normalized recovery = [(RecoveryMLN0128)/(RecoveryIS)] x 100%.
PA = mean peak area.
Table 2.3. Recovery of MLN0128 in pooled human plasma (n = 5).
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2.3.2.3 Calibration curve
The mean linear regression equation based on three individual calibration curves 
in three days was y = 0.516 (±0.005)x + 0.015 (±0.004) over the range of 0.100-50.0 ng 
mL-1 with a correlation coefficient of 0.999 (Figure 2.6). As shown in Table 2.4, the 
accuracy and precision of individual plasma calibrators were ≤ ± 6% and ≤ 7%, 
respectively.
66
Figure 2.6. Calibration curve for MLN0128.
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[Nominal]
(ng mL-1)
[Measured]
(ng mL-1)
SD
(ng mL-1)
Precision
(CV%)
Accuracy
(RE%)
0.100 0.101 0.008 7 0.6
0.200 0.203 0.006 3 1
0.500 0.49 0.02 3 -1
1.00 0.978 0.006 0.6 -2
2.50 2.5 0.1 3 1
5.00 4.89 0.04 0.6 -2
10.0 9.9 0.3 2 -1
25.0 26.4 0.5 2 6
50.0 48.8 0.7 1 -2
Table 2.4. Accuracy and precision of plasma calibrators.
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2.3.2.4 Assay accuracy and precision, and dilution integrity
As shown in Table 2.5, the intra-assay accuracy and precision were ≤ ± 4% and ≤
8%, and the inter-assay accuracy and precision were ≤ ±4% and ≤ 2%, respectively,
indicating the method developed was accurate and precise. The dilution studies showed
that the intra-assay accuracy and precision were ≤ ±3% and ≤ 3%, and the inter-assay
accuracy and precision were ≤ ±1%, and ≤ 1%, indicating the integrity of plasma samples
could be preserved in sample dilution.
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Intra-assaya
[Nominal]
(ng mL-1)
[Measured] 
(ng mL-1)
SD
(ng mL-1)
Precision
(CV%)
Accuracy
(RE%)
0.250 0.249 0.007 3 -0.6
3.00 2.94 0.03 1 -2
40.0 38 3 8 -4
250c 257 7 3 3
Inter-assayb
[Nominal]
(ng mL-1)
[Measured] 
(ng mL-1)
SD
(ng mL-1)
Precision
(CV%)
Accuracy
(RE%)
0.250 0.243 0.005 2 -3
3.00 2.88 0.05 2 -4
40.0 38.3 0.6 1 -4
250c 253 4 1 1
a Measured by five replicate measurements of each QC sample within a validation batch. 
b Measured by five parallel measurements of five identical QC samples at each concentration over three 
validation batches.
c Dilution QC was measured after a 10-fold dilution with pooled blank human plasma and the reported 
concentration was back-calculated by multiplying a factor of 10.
Table 2.5. Intra- and inter-assay accuracy and precision of MLN0128 in pooled human
plasma (n = 5).
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2.3.2.5 Stability
The stability studies for MLN0128 were conducted and the data were summarized
in Table 2.6. The stock solutions and plasma QCs were found to be stable by free 
standing on bench-top at room temperature for at least 24 h prior to sample preparation 
with recoveries of 99-101% and 94-105%, respectively. The plasma QCs were also stable 
for at least 24 h in autosampler set at 4°C post sample preparation with recoveries of 91­
104%. The recoveries of plasma QCs after 3 freeze-thaw cycles were 92-102%, and the 
long-term (2 months) storage at -20°C had recoveries of 95-101%. These studies showed 
that there were no significant losses of MLN0128 under the test conditions.
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Test conditions Temperature(oC) Sample
Reco
6 h
very ± SD (%)
24 h
Bench-top 23 Stock solutiona 100 ± 1 101 ± 1
Stock solutionb 101 ± 1 99 ± 1
Bench-top 23 Low QCc 98 ± 4 105 ± 5
High QCc 94 ± 1 97 ± 2
Autosampler 4 Low QC 94 ± 3 104 ± 2
High QC 93 ± 1 91 ± 1
Freeze-thaw cycles -20 to 23 Low QC 102 ± 2 94 ± 1
High QC 99 ± 1 92 ± 1
Long-term -20 Low QC 101 ± 1
High QC 95 ± 1
a The concentration of MLN0128 stock solution was 1.00 mg mL-1, which was measured by serial dilution 
to 1.00 ng mL-1 in mobile phase.
b The concentration of MLN0128 stock solution was 1.00 mg mL-1, which was measured by serial dilution 
to 50.0 ng mL-1 in mobile phase.
c The concentration of plasma low and high QCs were 0.250 ng mL-1 and 40.0 ng mL-1, respectively.
Table 2.6. Stability of MLN0128 under various test conditions (n = 5).
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2.3.3 Method application
The method developed was intended to support the proposed clinical studies of
MLN0128 in a “Randomized Pilot Phase 0 and FLT-PET/MRI Imaging Biomarker Study 
of MLN0128 in Recurrent Glioblastoma Multiforme” and a “Phase 1 Study of MLN0128 
with Bevacizumab” from the Case Comprehensive Cancer Center in response to the 
NCI/CTEP solicitation in 2013. Even though both proposals were not funded eventually,
the validated method may be used by the scientific community for preclinical and clinical
studies of MLN0128.
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2.4 Conclusions
A rapid and selective LC-MS/MS method has been developed for the quantitative
determination of MLN0128 in human plasma. In this method, MLN0128 and the IS were
extracted from human plasma by a liquid-liquid extraction procedure and separated by 
reversed phase chromatography with isocratic elution. Quantitation of MLN0128 was
carried out by internal calibration and positive electrospray ionization tandem mass 
spectrometry operated in MRM mode. This method has been validated according to US-
FDA guidance for industry on bioanalytical method validation. It may be used in clinical
studies of MLN0128 in human.
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CHAPTER III
DEVELOPMENT AND VALIDATION OF AN LC-MS/MS METHOD FOR
QUANTITATIVE DETERMINATION OF GS87, A NOVEL ANTINEOPLASTIC
AGENT, IN MOUSE PLASMA
3.1 Introduction
Glycogen synthase kinase-3 (GSK3), a serine/threonine protein kinase, originally 
identified as a key regulator in glycogen synthesis, later attributed to regulation of diverse 
signaling pathways involving signal transcription, gene expression, cell survival and 
apoptosis [1]. Dysregulation of GSK3 has been implicated in the development of various
diseases including diabetes, Alzheimer's, schizophrenia, leukemia and other cancers and
its selective inhibition has greater therapeutic potential in the treatment of these diseases
[2-6]. In the last decade, studies in several cancer lines indicated that the inhibition of 
GSK3 significantly reduces the tumor progression without affecting normal cells, which
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made it an attractive therapeutic target for clinical advancement in cancer research [7, 8]. 
Due to its increasing popularity, development of selective inhibitors for GSK3 has been 
actively pursued [9-11].
Acute myeloid leukemia (AML) is the maturational arrest of hematopoietic stem 
cells which results in failure to differentiate and overproliferation of myeloblasts [12].
GSK3 has long been pursued as a therapeutic target for AML due to its role in the 
regulation of leukemia stem cells through multiple pathways [13]. Majority of the 
investigational drug candidates for GSK3 inhibition suffers from non-selective inhibition 
of multiple protein kinases [14]. In the search for an effective GSK3 inhibitor a small 
molecule azole derivative, GS87, was custom designed based on known GSK3 inhibitors 
chemistry and structure-activity relationships. GS87 is a highly specific GSK3 inhibitor, 
shown to induce extensive differentiation of AML cells as compared to existing GSK3 
inhibitors. GS87 acts by modulating key GSK3 target proteins without affecting normal 
cells. Although the reason for its enhanced activity is unknown at this time, early mouse 
studies proved its tremendous potential for clinical advancement [15].
To support the pre-clinical studies of GS87 in mouse, a sensitive and reliable 
analytical method is required. Up to date, there is no published analytical method 
available for the measurement of GS87. This work describes the development and 
validation of an LC-MS/MS method for the quantitation of GS87 in mouse plasma. 
T6447952, a structural analog of GS87, was chosen as the internal standard for the 
method. A liquid-liquid extraction procedure was developed for the extraction of GS87 
and the IS from mouse plasma using hexane as solvent. Both the analyte and the IS were
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separated isocratically on a Waters XTerra® MS C8 column using acetonitrile and 5.00 
mM ammonium formate (35:65, v/v) as mobile phase. Quantitation was carried out by 
multiple-reaction-monitoring (MRM) mode of positive turbo-spray tandem mass 
spectrometry. The developed method has been applied to the measurement of GS87 
concentrations in a preliminary mouse study.
3.2 Experimental
3.2.1 Chemicals and solutions
GS87 (C16H11N5O2S, 99.5%) was purchased from Sigma-Aldrich (St. Louis, MO, 
USA). T6447952 (as an internal standard, IS, C14H9N5O2S2, 90%) was purchased from 
Enamine (Monmouth Junction, NJ, USA). (Figure 3.1). LC/MS-grade Acetonitrile 
(ACN), HPLC-grade water, ACS-grade dimethylsulfoxide (DMSO) and hexane were 
purchased from Fisher Scientific (Pittsburgh, PA, USA). Ammonium formate was from
Sigma-Aldrich (St. Louis, MO, USA). Six pooled blank mouse plasmas lots containing 
sodium heparin anticoagulant with specific lot numbers (IR11-BCNaH-0928, 11140-01, 
11140-02, 11140-03, 11140-04, and 11140-05) were purchased from Innovative Research
(Novi, MI, USA).
The stock standard solution of GS87 (1.00 mg mL-1) and stock IS solution (1.00 
mg mL-1) were prepared individually by dissolving an appropriate amount of compound
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Figure 3.1. Structures of GS87 and IS.
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in a known volume of DMSO. The stock standard solutions were kept in amber glass 
autosampler vials and stored at -20oC. The working standard solutions of GS87 (5.00 μg 
mL-1, 500 ng mL-1, and 50.0 ng mL -1) were prepared by serial dilution of the stock 
standard solution of GS87 with ACN. The working IS solution (1.00 μg mL-1) was 
prepared by serial dilution of the stock IS solution with ACN. The working standard 
solutions were kept in amber glass autosampler vials. The standard solutions of GS87 
(25.0, 50.0, 60.0, 100, 250, 350, 500, 1.00x 103, 2.00x 103, and 2.50x 103 ng mL-1) were 
prepared by serial dilution of the working standard solutions of GS87 with the mobile 
phase. The IS solution (50 ng mL-1) was prepared by serial dilution of the working IS 
solution with the mobile phase. The standard solutions were prepared in disposable 
borosilicate glass tubes (10 x 75 mm, VWR, Randor, PA, USA). The stock solution of 
ammonium formate (0.100 M) was prepared by dissolving an appropriate amount of 
ammonium formate salt in a known volume of water and stored in a refrigerator at 4oC. 
The working solution of ammonium formate (5.00 mM) was prepared by dilution of the 
stock solution with water and adjusted to pH 2.8 using formic acid, if necessary. The 
mobile phase for the chromatographic separation was prepared by mixing ACN and 
ammonium formate working solution at a ratio of 35:65 (v/v).
3.2.2 Preparation of plasma calibrators and quality controls
GS87 plasma calibrators (0.00, 2.50, 5.00, 10.0, 25.0, 50.0, 100, and 250 ng mL-1) 
were prepared by addition of 10.0 μL of the mobile phase (for the blank of GS87) or each 
standard solution of GS87 (25.0, 50.0, 100, 250, 500, 1.00x 103, and 2.50x 103 ng mL-1)
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to 90.0 μL of pooled blank mouse plasma. GS87 plasma quality controls (QCs) (6.00, 
35.0, 200 ng mL-1) were prepared by addition of 10.0 μL of the standard solution of 
GS87 (60.0, 350, and 2.00x 103 ng mL-1) to 90.0 μL of pooled blank mouse plasma. 
Aliquots (100.0 μL) of plasma calibrators and QCs were prepared in disposable 
borosilicate glass tubes (13 x 100 mm, VWR, Randor, PA, USA), vortex-mixed and 
stored at -20oC before use.
3.2.3 Plasma sample preparation
Plasma calibrators, QCs, and mouse plasma samples were thawed to room 
temperature and extracted using the following liquid-liquid extraction procedure. For 
each 100 μL of plasma sample, 10.0 μL of the IS solution (50.0 ng mL-1) was added 
except the double blank where 10.0 μL of the mobile phase was added. The samples were 
vortex-mixed for 30 s, followed by addition of 2 mL of hexane and mixed in a multi-tube 
vortex mixer (Troemner, Thorofare, NJ, USA) for 5 min. The samples were centrifuged 
(Sorvall, Thermo Scientific, Waltham, MA, USA) at 4816 x g for 5 min at 4oC. The 
organic phase (upper layer) was transferred into a fresh borosilicate glass tube and dried 
in a TurboVap® LV evaporator (Caliper Life Sciences, Hopkinton, MA, USA) at 30oC 
under nitrogen gas at a pressure of 15 psi for 15 min. The sample residue was 
reconstituted in 100 μL of the mobile phase for subsequent LC-MS/MS analysis.
3.2.4 Instrumentation
84
The instrumentation system used in this work consisted of a Shimadzu 
Prominence UFLC unit (Shimadzu, Columbia, MD, USA) with a controller (CBM-20A), 
two binary pumps (LC-20AD), and an autosampler (SIL- 20AC), and an ABSciex API 
3200 turbo-ion-spray® triple quadrupole tandem mass spectrometer (ABSciex, Foster 
City, CA, USA) equipped with an electrospray ionization (ESI) probe and a syringe 
pump. Both systems were connected using PEEK tubing (0.0625 in. o.d. x 0.01 in. i.d.). 
The LC-MS/MS system operation, data acquisition, and processing were done by 
ABSciex Analyst® software (version 1.5.1).
Analytical separation of GS87 and IS was carried out isocratically at room 
temperature on a Waters (Milford, MA, USA) XTerra® MS C8 column (2.1 × 50 mm, 3.5 
μm) connected to a Waters XTerra® MS C18 guard column (2.1 × 10 mm, 3.5 μm) using 
a mobile phase consisted of ACN and 5.00 mM ammonium formate (35:65, v/v) at a flow 
rate of 0.200 mL min-1. The injection volume of 5.00 μL was used for each analysis.
The mass spectrometer was operated under positive electrospray ionization (ESI+) 
mode. The instrument settings for compound-dependent parameters were optimized by 
direct infusion of GS87 (5.00 μg mL-1) and IS (5.00 μg mL-1) in the mobile phase at a 
flow rate of 10.0 μL min-1 using the syringe pump, and source-dependent parameters 
were optimized by flow injection analysis of GS87 and IS mixture (100 ng mL-1). The 
optimized compound-dependent parameters for GS87 and IS were as follows: 
declustering potential at 55 V and 70 V; entrance potential at 8 V and 5 V; collision 
energy at 35 eV and 30 eV; and collision cell exit potential at 18 V and resolution at 0.7 
unit for both GS87 and the IS. The optimized source-dependent parameters were as
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follows: curtain gas at 30 psi; collision gas at 6 psi; ion spray voltage at 5500 V; source 
temperature at 700oC; sheath gas at 45 psi; and desolvation gas at 45 psi. Analyte 
quantitation was carried out by multiple-reaction-monitoring (MRM) mode using the 
following mass transitions: m/z 338 > 123 for GS87 and m/z 344 > 123 for the IS, with a
dwell time of 100 ms for each analyte.
3.2.5 Animal study
The animal study protocol for this work was approved by the Case Western 
Reserve University Institutional Animal Care and Use Committee (IACUC). Six-week- 
old female NOD-scid IL2Rγnull (NSG) mice were obtained from Jackson Laboratories 
(Bar Harbor, Maine, USA). The injectable GS87 (20.0 mM) was prepared in 20% DMSO 
aqueous solution which was given to each mouse as a single-bolus intraperitoneal (i.p.) 
injection at a dose of 50 mg kg-1. The mouse blood samples were collected via cardiac 
puncture under ether anesthesia into 1.5 mL microcentrifuge tubes containing heparin as 
anti-coagulant at the following time points: 0 (pre-dose), 5, 30, 60, 180 and 360 min. For
the pre-dose sample, the mouse was injected with only 20% DMSO aqueous solution 
without GS87. One whole blood sample (ca. 1 mL) was drawn from the single mouse at 
each time point, which was placed in ice immediately. The whole blood samples were 
processed within 15 min of collection by centrifugation at 1000 × g and 4 oC for 10 min. 
The harvested plasma samples (ca. 0.5 mL each) were stored at -80 oC until analysis.
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3.3 Results and discussion
3.3.1 Method development
3.3.1.1 Chemical properties of the analyte and the IS
The LogP and pKa (of conjugate acid) values predicted by the ACDLabs® 
software (V 12.02, Advanced Chemistry Development, Inc., Toronto, Ontario, Canada) 
were 3.93 and 5.2 for GS87; and 3.61 and 5.2 for T6447952, respectively. The LogP 
values suggested that these compounds are hydrophobic in nature, and the pKa values 
suggested that these compounds are more readily protonated than deprotonated at acidic 
pH environment. Based on these properties, suitable solvents, mobile phase, and 
chromatographic column were selected for the analysis.
3.3.1.2 Mass spectrometric detection
The optimization of GS87 and the IS responses was done by infusion analysis. 
The full-scan spectra of GS87 and the IS revealed the formation of protonated molecules, 
[GS87+H]+ at m/z 338 and [IS+H]+ at m/z 344 (Figures 3.2A and 3.2B). These precursor 
ions were further fragmented in the collision cell into predominant product ions at m/z 
123 and m/z 123, respectively. Therefore, the mass transitions of m/z 338 > 123 for GS87
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Figure 3.2. The mass spectra of precursor and product ions of GS87 and IS.
88
and m/z 344 > 123 for the IS were used for the quantitation of GS87 by tandem mass 
spectrometry in MRM mode.
3.3.1.3 Liquid chromatography
Based on the hydrophobic nature of GS87 and the IS, several reversed-phase 
chromatographic columns were evaluated for optimum separation. In this work, Waters 
XTerra® MS C18, Acquity UPLCTM RP 18, Waters XBridgeTM C8, and Waters XTerra® 
MS C8 columns were tested. Even though all of these columns showed reasonable 
retention time and sufficient resolution, Waters XTerra® MS C8 column was chosen 
because of its symmetrical peak shape and relatively higher signal response as compared 
to others. Ammonium formate was used as a buffer in the mobile phase not only to 
maintain a low pH value for the formation of protonated GS87 and the IS but also to give 
greater sensitivity for MS detection as compared to the use of formic acid. The 
percentage of ammonium formate buffer and ACN was optimized for separation 
efficiency and matrix effect (see Section 3.3.1.5.). Baseline resolution was achieved using 
ACN and 5.00 mM ammonium formate at a ratio of 35:65 (v/v). Therefore, 
chromatographic separation was carried out using waters XTerra® MS C8 column with 
mobile phase consisting of ACN and 5.00 mM ammonium formate (35:65, v/v) at a flow 
rate of 0.200 mL min-1 with the retention times for the IS and GS87 at 4.51 min. and 6.48 
min., respectively. The total run time of each instrumental analysis was 8.00 min.
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3.3.1.4 Plasma sample preparation and plasma volume
In this work, protein precipitation (PPT) and liquid-liquid extraction (LLE)
sample extraction methods were evaluated for extraction efficiency and sample recovery. 
PPT resulted in cloudy solution after the drying step, requiring additional sample cleanup, 
whereas, LLE yielded cleaner sample, so, LLE was chosen for further studies. In LLE, 
several extraction solvents (methyl tert-butyl ether, ethyl acetate, and hexane) were tested 
either alone or in combination of different ratios to assess the extraction efficiency. Of 
all, hexane yielded higher efficiency; therefore, it was chosen as the extraction solvent for 
the sample preparation.
Since the animal pharmacokinetic study was carried out in conjunction with other 
animal tissue studies, a relatively large volume of plasma was available from each mouse 
in this work. In case of single mouse pharmacokinetic study, microdialysis probe should 
be considered for drug sampling [16] or nano-LC-MS/MS should be used for small 
plasma sample (ca. 2 μL) analysis [17, 18].
3.3.1.5 Influence of non-matrix solvent on plasma calibrators and QCs
The influence of non-matrix solvent on plasma calibrators and QCs was assessed 
by comparing the measured concentrations of GS87 in 0%, 5% and 10% non-matrix 
solvent plasma calibrators. 0% non-matrix solvent plasma calibrators were prepared by 
drying the solvent working standard solution under nitrogen flow followed by the 
addition of pooled blank plasma, 5% or 10% non-matrix solvent plasma calibrators were
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prepared by addition of 5% or 10% solvent working standard solution to pooled blank 
plasma (n = 3). All the samples were processed using the sample preparation procedure 
described in Section 3.2.3. The measured concentrations were calculated using the 
calibration equation derived from the calibration curve based on 10% non-matrix solvent 
plasma calibrators. The results indicated that the relative error (%RE) and coefficients of 
variation (CVs) were ≤ ±1 % and ≤ 2% for 0% non-matrix solvent plasma calibrator, ≤ 
±4 % and ≤ 3% for 5% non-matrix solvent plasma calibrators, and ≤ ±2 % and ≤ 2% for 
10% non-matrix solvent plasma calibrators. Since the US-FDA guidance on 
bioanalytical method validation permits RE (%) ≤ ±15% and CV (%) ≤15% for analyte at 
concentrations higher than that of LLOQ; therefore, the use of 10% non-matrix solvent 
plasma calibrators and QCs were acceptable in this work.
3.3.1.6 Matrix interferences
In this work, a mobile phase composition of ACN and 5.00 mM ammonium
formate (40:60, v/v) was initially tested, which yielded baseline resolved peaks for GS87 
and the IS with short retention times; however, when it was applied to the separation of 
analytes in plasma matrice, severe matrix interferences were encountered during the first 
4 min of the chromatographic run (Figure 3.3). To remove the interferences, several 
extraction solvents (e.g., methyl tert-butyl ether, ethyl acetate, and hexane) were 
examined either alone or in combination. Since all of the solvents yielded similar matrix
interferences, the ratio of ACN to 5.00 mM ammonium formate in the mobile was then
adjusted to 35:65 (v/v), which delayed the elution of GS87 and the IS and allowed matrix
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interferences to pass the column within the first 4.00 min of the chromatographic run. In 
this method, the eluate of the first 4.00 min from the chromatographic column was 
diverted to waste in order to prevent the contamination of the mass spectrometer. The 
mobile phase composition of ACN and 5.00 mM ammonium formate at a ratio of 35:65 
(v/v) was adopted for the method, which resulted in the matrix effect at a negligible level 
(see data in Section 3.3.2.2.).
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Figure 3.3. The mass chromatograms of post-column infusion of GS87 (A) injection of
10.0 μL of the mobile phase; and (B) injection of 10.0 μL of hexane-extract of blank
mouse plasma.
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3. 3.2 Method validation
The LC-MS/MS method developed was validated according to the guidance set 
forth by the US-FDA for industry on bioanalytical method validation [19].
3.3.2.1 Selectivity and lower limit of quantitation
The selectivity of the method was evaluated by observing interferents at the mass 
transitions and the retention times of GS87 and the IS in six individual pooled blank 
mouse plasma matrices. As illustrated in Figure 3.4, there were no detectable 
interferences observed for both GS87 and the IS.
The lower limit of quantitation (LLOQ) of the method was defined as the lowest 
calibrator (2.50 ng mL-1) of the calibration curve, which was confirmed by measuring 
GS87 in six individual lots of pooled blank mouse plasma samples. The accuracy and 
precision of each lot of plasma at LLOQ as summarized in Table 3.1, which were ≤±19% 
and ≤5%, well within the limit set by the US-FDA.
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Figure 3.4. The mass chromatograms of GS87 and IS in mouse plasma (A) double blank 
plasma (with neither GS87 nor IS); (B) single blank plasma (with IS only 50.0 ng mL-1); 
and (C) at LLOQ (GS87 at 2.50 ng mL-1 and the IS at 50.0 ng mL-1).
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Plasma
matrix
[Nominal] 
(ng mL-1)
[Measured] 
(ng mL-1)
SD
(ng mL-1)
Precision
(CV%)a
Accuracy
(RE%)b
Lot 1 2.50 2.06 0.06 3 -17
Lot 2 2.50 2.21 0.08 4 -11
Lot 3 2.50 2.02 0.07 3 -19
Lot 4 2.50 2.08 0.09 4 -17
Lot 5 2.50 2.10 0.10 5 -16
Lot 6 2.50 2.09 0.07 3 -16
a CV = (standard deviation/mean) x 100%.
b RE = [(measured - nominal)∕(nominal)] x 100%.
Table 3.1. Accuracy and precision of GS87 at LLOQ in six individual lots of pooled 
mouse plasma (n = 5).
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3.3.2.2 Matrix effect and Recovery
The matrix effect (either signal suppression or enhancement) can be evaluated by 
both absolute and IS normalized matrix factors. The mean peak area of GS87 in extracted 
plasma matrix over the mean peak area of GS87 in mobile phase gives the absolute
matrix factor of GS87. The absolute matrix factor of GS87 over the absolute matrix
factor of the IS gives the IS normalized matrix factor. Matrix effect study was conducted 
using pooled blank mouse plasma lot for low (6.00 ng mL-1), mid (35.0 ng mL-1) and 
high (200 ng mL-1) QC concentrations, and then extended to five more pooled blank 
mouse plasma lots. As shown in Table 3.2, the absolute matrix factors were ranged from 
0.82-1.01 for GS87, 0.84-1.02 for the IS, and the IS normalized matrix factors were 0.93­
1.03. The data revealed that the matrix suppression could be corrected by using the IS.
The recovery of the analytes from sample matrix can be calculated as both 
absolute and IS normalized recoveries. The mean peak area of GS87 in plasma matrix 
(i.e., the analyte was spiked in before extraction pooled plasma) over the mean peak area 
of GS87 in the extracted plasma matrix (i.e., the analyte was spiked in after extraction of 
pooled plasma) gives the absolute recovery of GS87. The absolute recovery of GS87 
over the absolute recovery of the IS gives the IS normalized recovery. Recovery study 
was conducted in pooled blank mouse plasma for low (6.00 ng mL-1), mid (35.0 ng mL-1) 
and high (200 ng mL-1) QC concentrations. As shown in Table 3.3, the absolute 
recoveries were ranged from 64-66% for GS87, 61-64% for the IS and the IS normalized
recoveries were 103-106%. The data indicated that the low absolute recoveries could be 
corrected by the use of the IS.
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Plasma
matrix
[GS87]
(ng mL-1)
mfGS87
± SDa
MFIS 
± SDb
IS Normalized MF 
± SDc
Lot 1 6.00 0.89±0.01 0.95±0.01 0.94±0.02
35.0 0.850±0.004 0.910±0.008 0.93±0.01
200 0.82±0.02 0.84±0.01 0.97±0.04
Lot 2 6.00 0.85±0.04 0.87±0.02 0.97±0.03
35.0 0.84±0.01 0.890±0.005 0.94±0.02
200 0.89±0.05 0.88±0.04 1.01±0.08
Lot 3 6.00 0.93±0.02 0.97±0.01 0.96±0.01
35.0 0.95±0.02 0.980±0.009 0.96±0.01
200 0.970±0.008 0.97±0.02 0.99±0.02
Lot 4 6.00 0.96±0.02 0.97±0.03 1.00±0.01
35.0 0.99±0.04 0.98±0.02 1.01±0.03
200 0.980±0.008 0.95±0.01 1.03±0.02
Lot 5 6.00 1.01±0.03 1.02±0.04 0.99±0.02
35.0 1.00±0.01 1.01±0.01 0.99±0.07
200 0.960±0.009 0.95±0.01 1.01±0.01
Lot 6 6.00 0.98±0.03 1.00±0.02 0.980±0.009
35.0 0.960±0.004 0.980±0.004 0.970±0.005
200 0.93±0.02 0.95±0.01 0.98±0.01
a MFGS87 = (mean peak area of GS87 in extracted plasma matrix)/(mean peak area of GS87 in the mobile 
phase).
b MFIS = (mean peak area of IS in extracted plasma matrix)/(mean peak area of IS in the mobile phase). 
c IS normalized MF = MFGS87/MFIS.
Table 3.2. Matrix factors of GS87 in six different lots of pooled mouse plasma (n = 5).
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[GS87]
(ng mL-1)
RecoveryGS87a
± SD (%)
RecoveryISb 
± SD (%)
IS Normalized Recoveryc 
± SD (%)
6.00 66 ± 5 64 ± 4 103 ± 9
35.0 65 ± 3 61 ± 2 106 ± 3
200 64 ± 2 62 ± 1 104 ± 4
a RecoveryGS87= [(mean peak area of GS87 in plasma matrix)/(mean peak area of GS87 in extracted 
plasma matrix)] x 100%.
b RecoveryIS= [(mean peak area of IS in plasma matrix)/( mean peak area of IS in extracted plasma 
matrix)] x 100%.
c IS normalized recovery= [(RecoveryGS87)/(RecoveryIS)] x 100%.
Table 3.3. Recovery of GS87 in pooled mouse plasma (n = 5).
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3.3.2.3 Precision, accuracy, and dilution integrity studies
Intra-assay accuracy and precision were determined by five replicate injections of 
QC samples at each concentration (6.00, 35.0, 200, and 1.25 x103 ng mL-1). Inter-assay 
accuracy and precision were determined by five parallel injections from five identical 
QCs at each concentration (6.00, 35.0, 200, and 1.25 x 103 ng mL-1) over three separate 
days. The use of dilution QC (1.25 x 103 ng mL-1) was to check the dilution integrity. 
Since the concentration of the dilution QC was beyond the upper limit (250 ng mL-1) of 
the linear calibration curve, it was diluted by 1:25 using the pooled blank mouse plasma 
before the analysis. As shown in Table 3.4, the intra-assay accuracy and precision were 
≤±3% and ≤4%, and the inter-assay accuracy and precision were ≤±5% and ≤6%, 
respectively. The dilution integrity was well preserved with the intra-assay accuracy and 
precision of ≤±1% and ≤2%, and the inter-assay accuracy and precision of ≤±3% and 
≤2%, respectively.
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Intra-assaya
[Nominal]
(ng mL-1)
[Measured] 
(ng mL-1)
SD
(ng mL-1)
Precision
(CV%)
Accuracy
(RE%)
6.00 5.9 0.2 4 -2
35.0 34.0 0.6 2 -3
200 195 6 3 -2
1.25 x 103c 1.23 x 103 0.02 x 103 2 -1
Inter-assayb
[Nominal]
(ng mL-1)
[Measured] 
(ng mL-1)
SD
(ng mL-1)
Precision
(CV%)
Accuracy
(RE%)
6.00 5.7 0.1 3 -4
35.0 33 2 6 -5
200 190 7 4 -5
1.25 x 103c 1.21 x 103 0.02 x 103 2 -3
a Measured by five replicate measurements of each QC sample within a validation batch. 
b Measured by five parallel measurements of five identical QC samples at each concentration over three 
validation batches.
c Dilution QC was measured after a 25-fold dilution with pooled blank plasma and the reported 
concentration was back-calculated by multiplying a factor of 25.
Table 3.4. Intra- and inter-run accuracy and precision of GS87 in pooled mouse plasma
(n = 5).
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3.3.2.4 Calibration curve
GS87 calibration curve was constructed using seven non-zero plasma calibrators, 
one single-blank plasma (with the IS only), and one double-blank plasma (without GS87 
or the IS). The concentrations of non-zero calibrators were 2.50, 5.00, 10.0, 25.0, 50.0,
100 and 250 ng mL-1. The linear calibration range of 2.50-250 ng mL-1 was established 
for GS87 in mouse plasma with the IS by plotting the peak area ratios of GS87 to the IS 
versus the concentrations of GS87. The calibration equation derived from three individual 
calibration curves on three different days with 1/x (the reciprocal of GS87 concentration) 
weighting was y = 0.0146 (±0.0006)x-0.0068 (±0.0058) with a correlation coefficient of 
≥0.999 (Figure 3.5). The accuracy and precision of individual GS87 calibrators were 
≤±7% and ≤5% (Table 3.5).
102
Figure 3.5. Calibration curve for GS87.
103
[Nominal]
(ng mL-1)
[Measured]
(ng mL-1)
SD
(ng mL-1)
Precision
(CV%)
Accuracy
(RE%)
2.50 2.7 0.1 5 7
5.00 4.90 0.09 2 -2
10.0 9.90 0.08 1 -1
25.0 24.4 0.9 4 -2
50.0 49 2 4 -2
100 100 2 2 -0.4
250 252 5 2 1
Table 3.5. Accuracy and precision of plasma calibrators.
104
3.3.2.5 Stability
The stability of the stock standard solution of GS87 (1.00 mg mL-1) and GS87 
plasma QCs (6.00 and 200 ng mL-1) were investigated. The stock standard solution was 
kept on bench top (23oC) for 6 and 24 hrs before diluting to 10.0 ng mL-1 and 50.0 ng mL- 
1. The QCs were kept on bench top (23oC) and autosampler (4oC) for 6 and 24 hrs after 
sample preparation. For freeze-and-thaw cycles, the QCs were frozen (-20oC) for 24 hrs 
then thawed at room temperature (23oC) unassisted. For long-term storage study, the 
QCs were stored at -20oC and tested up to five months.
The stability of GS87 was determined by comparing the mean-peak-area ratios of 
GS87 to the IS with triplicate measurements of test samples over those of freshly 
prepared samples and multiplying by 100%. As shown in Table 3.6, the recoveries of 
stock standard solutions were 94-101%, and the recoveries of QCs at two concentrations 
(6.00 and 200 ng mL-1) were 92-97% for bench top (23oC), and 94-96% for autosampler 
(4oC). The recoveries of three freeze-and-thaw cycles were 90-102% and the recoveries 
of five-month storage (-20oC) were 101-102%. These results indicated that there were no 
significant losses of GS87 under the testing conditions.
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Test conditions Temperature(oC) Sample
Recovery ± SD (%)
6 h 24 h
Bench-top 23 Stock solutiona 99 ± 0.3 94 ± 1
Stock solutionb 100 ± 1 101 ± 1
Bench-top 23 Low QCc 94 ± 2 92 ± 4
High QCc 97 ± 1 93 ± 1
Autosampler 4 Low QC 96 ± 2 95 ± 3
High QC 96 ± 1 94 ± 2
Freeze-thaw cycles -20-23 Low QC 90 ± 2
High QC 102 ± 2
Long-term -20 Low QC 101 ± 3
High QC 102 ± 1
a The concentration of GS87 stock solution was 1.00 mg mL-1, which was measured by serial dilution to 
10.0 ng mL-1 in the mobile phase.
b The concentration of GS87 stock solution was 1.00 mg mL-1, which was measured by serial dilution to 
50.0 ng mL-1 in the mobile phase.
c The concentration of plasma low and high QCs were 6.00 and 200 ng mL-1, respectively.
Table 3.6. Stability of GS87 under various test conditions (n = 3).
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3.3.3 Application to animal study
The validated LC-MS/MS method was applied to the measurement of GS87
concentrations in plasma samples from a mouse study. In this work, mouse plasma
samples, along with calibrators, and QCs were thawed to room temperature, prepared by 
liquid-liquid extraction procedure described in the Section 3.2.3 and analyzed using the 
validated method. The concentrations beyond the upper limit of quantitation (i.e., 250 ng 
mL-1) were diluted by a ratio of 1:50 using pooled blank mouse plasma. Figure 3.6 shows 
the concentration-time profile of GS87 in mouse plasma.
Since the dose of GS87 (50 mg kg-1) used in this preliminary study was 10 to 50 
times higher than that of normal pharmacokinetic study, the resulting plasma GS87 
concentrations were higher than the upper limit of the calibration curve. However, this 
did not imply that the dose of GS87 in the future studies would be kept at such high level. 
The calibration range of the method would be well suited for the study of GS87 at lower
doses.
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Figure 3.6. The concentration-time profile of GS87 in mice after a single intraperitoneal 
injection of GS87 at the dose of 50 mg kg-1.
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3.4 Conclusions
An LC-MS/MS method for the quantitative determination of GS87 in mouse 
plasma has been developed. In this method, GS87 and the IS were extracted by liquid- 
liquid extraction procedure, separated isocratically on a Waters XTerra® MS C8 column, 
and quantified by positive turbo-ion-spray tandem mass spectrometry in MRM mode. 
The developed method has been validated according to the US-FDA guidance for 
industry on bioanalytical method validation and has been successfully applied to the 
determination of GS87 in an animal study.
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CHAPTER IV
AN LC-MS/MS METHOD FOR SIMULTANEOUS DETERMINATION OF
CURCUMIN, CURCUMIN GLUCURONIDE AND CURCUMIN SULFATE IN A
PHASE II CLINICAL TRIAL
4.1 Introduction
Turmeric has been used for centuries in Asia due to its wide range of medicinal 
properties [1]. Its principal constituent, curcumin, has gained a lot of popularity in the 
past two decades because of its multiple biological and pharmacological activities which 
can modulate multiple cell-signaling pathways through direct or indirect interaction with 
multiple molecular targets [2, 3]. Although curcumin suffers from poor bioavailability by 
rapid conversion into its metabolites, curcumin glucuronide (COG) and curcumin sulfate 
(COS), studies indicated that these metabolites may retain some of the pharmacological 
activity of curcumin and responsible for its biological activity [4-7].
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Curcumin's anticancer potential has garnered great interest because of its long­
term human consumption, proven safety, and lower incidence of certain types of cancers 
based on epidemiological studies [8]. Its anticancer activities result from multiple 
biochemical mechanisms involving mutagenesis, tumorigenesis, metastasis, cell cycle 
regulation, apoptosis, and autophagy. Curcumin targets several transcription factors NF- 
kB, AP-1, STAT3 and sp-1, growth factor receptors, enzymes, and cell surface adhesion 
molecules [9, 10]. Studies showed that curcumin can selectively kill tumor cells without 
affecting normal cells [11]. The current phase II clinical trial [12] was designed to study 
the efficacy and tolerability of curcumin and vitamin D3 combination in patients with 
early-stage chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) 
where curcumin may upregulate intracellular vitamin D receptor (VDR) cells making 
them more susceptible to incoming vitamin D3 in a synergistic activity [13].
To support clinical studies of curcumin as a therapeutic agent, a sensitive 
analytical method is required. There are several published analytical methods available 
for the measurement of curcumin in plasma including the measurement of total free 
curcumin and curcumin metabolites by enzymatic hydrolysis [14, 15] and direct 
measurement of curcumin, COG, and COS simultaneously [16]. However, the former one 
requires multiple runs for the measurements of curcumin and metabolites concentrations 
and suffers from long enzymatic reaction times and varying enzyme activity; and the later 
one has low analyte recoveries and severe matrix effect that could not be corrected by the 
choice of internal standard, hence compromising the accuracy of analytical data.
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In this work, we describe the development and validation of an improved liquid 
chromatography-tandem mass spectrometry method for simultaneous determination of 
curcumin, COG, and COS in human plasma. In this method, a simpler protein 
precipitation protocol was used for sample preparation, two internal standards (curcumin- 
d6 and BPAG-d6) were implemented for internal calibration of curcumin, COG, and COS, 
respectively. The analytical separation was carried out on a Waters XTerra® MS C18 
column using gradient elution with methanol and 10.0 mM ammonium formate (pH 3.0) 
at a flow rate of 0.250 mL min-1. The method developed has demonstrated a complete 
correction of sample matrix effects and excellent recoveries for curcumin, COG, and 
COS. This method has been successfully applied to the measurement of curcumin, COG, 
and COS in human plasma samples from a phase II clinical trial.
4.2 Experimental
4.2.1 Chemicals and standard solutions
Curcumin (C21H20O6, > 98%) was purchased from Sigma-Aldrich (St. Louis, MO, 
USA). Curcumin β-D-glucuronide (COG, C27H28O12, > 96%), curcumin sulfate 
tetrabutylammonium (COS, C37H55NO9S, > 98%), curcumin-d6 (C21H14D6O6, > 98%) and 
bisphenol A-d6 β-D-glucuronide (BPAG-d6, C21H18D6O8, > 95%) were purchased from 
Toronto Research Chemicals (Toronto, ON, Canada). (Figure 4.1). HPLC-grade water,
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Figure 4.1. Structures of curcumin, COG, COS, curcumin-d6, and BPAG-d6.
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LC-MS grade methanol, ACS-grade formic acid and dimethyl sulfoxide (DMSO) were 
purchased from Fisher Scientific (Pittsburgh, PA, USA). Ammonium formate was from 
Sigma-Aldrich (St. Louis, MO, USA). Blank pooled human plasma and six lots of blank 
human plasma (EDTA-treated) were purchased from Innovative Research (Novi, MI, 
USA).
Since curcumin is sensitive to light [17], all curcumin containing solutions and 
samples were kept in amber glass vials (Sigma-Aldrich, St. Louis, MO, USA) and 
prepared under dim light.
The standard stock solutions (1.00 mg mL-1) of curcumin and COG, and IS stock 
solution of curcumin-d6 (1.00 mg mL-1) were prepared individually by dissolving an 
appropriate amount of compound in a known volume of methanol. The standard stock 
solution (1.00 mg mL-1) of COS was prepared by dissolving an appropriate amount of 
curcumin sulfate tetrabutylammonium with a mass correction factor of 0.648 in a known 
volume of methanol. The IS stock solution of BPAG-d6 (1.00 mg mL-1) was prepared by 
dissolving an appropriate amount of compound in a known volume of DMSO. The 
solutions were stored at -20oC before use.
The stock solution of ammonium formate (0.100 M) was prepared by dissolving 
an appropriate amount of ammonium formate salt in a known volume of HPLC-grade 
water and stored at 4oC. The working solution of ammonium formate (10.0 mM) was 
prepared freshly by a 10-fold dilution of the stock solution with HPLC-grade water and 
adjusted to pH 3.0 using formic acid. The mobile phase consisted of methanol and 10.0 
mM ammonium formate solution (pH 3.0). The dilution solution was prepared by
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combining methanol and ammonium formate solution (10.0 mM, pH 3.0) (1:1 v/v). The 
protein precipitation solution was prepared by mixing methanol and formic acid (1000:1 
v/v) and made freshly to prevent esterification reaction between methanol and formic 
acid [18].
The mixed standard working solution (100.0 μg mL-1) was prepared as a mixture 
of curcumin, COG, and COS by combining an appropriate amount of each of the standard 
stock solution and diluting with methanol. The IS working solutions (100.0 μg mL-1) of 
curcumin-d6 and BPAG-d6 were prepared individually by dilution of the standard stock 
solutions with methanol. The mixed standard solutions (50.0, 100, 150, 200, 500, 1.00x 
103, 1.10x 103, 2.50x 103, 5.00x 103, 8.00x 103 ng mL-1, and 10.0x 103 ng mL-1) were 
prepared by serial dilution of the mixed standard working solution with the dilution 
solution. The mixed internal standard (IS) solution was prepared as a mixture of 
curcumin-d6 (500 ng mL-1) and BPAG-d6 (2.00 μg mL-1) by serial dilution of the IS 
working solutions with the dilution solution.
4.2.2 Preparation of plasma calibrators and quality controls
Plasma calibrators (2.50, 5.00, 10.0, 25.0, 50.0, 125, 250, and 500 ng mL-1) and 
plasma quality controls (7.50, 55.0, and 400 ng mL-1) were prepared by mixing 200 μL of 
pooled blank human plasma and 10.0 μL of the corresponding mixed standard solution.
Single blank plasma calibrator (plasma matrix with only the IS) and double blank 
plasma calibrator (plasma matrix with neither analyte or the IS) were prepared by mixing
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200 μL of pooled blank human plasma with 10.0 μL of the dilution solution. Plasma
calibrators and quality controls were prepared in 1.5 mL Eppendorf tubes and stored at -
70oC before use.
4.2.3 Sample preparation
Plasma samples (i.e., calibrators, quality controls, or patient samples) were 
thawed to room temperature. For each plasma sample, 10.0 μL of the mixed IS solution 
(curcumin-d6 at 25.0 ng mL-1 and BPAG-d6 at 100 ng mL-1) was added except patient 
sample and the double blank where 10.0 μL of the dilution solution was added and 
vortex-mixed for 30 s. The samples were deproteinized with 800 μL of protein 
precipitation solution by mixing in a multi-tube vortex mixer (Troemner, Thorofare, NJ, 
USA) for 5 min, followed by centrifugation (Sorvall ST40R, Thermo Scientific, Waltham, 
MA, USA) at 17000 x g at 4oC for 10 min. The supernatant was transferred into a fresh 
amber glass vial and dried in a TurboVap® LV evaporator (Caliper Life Sciences, 
Hopkinton, MA, USA) at 20oC under nitrogen gas flow at a pressure of 17 psi for 45 min. 
The residue was reconstituted in 100 μL of the dilution solution, vortex mixed for 30 s 
and centrifuged at 17000 x g at 4°C for 10 min. The solution was transferred into an
amber glass vial for LC-MS/MS analysis.
4.2.4 Instrumentation
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The liquid chromatography-tandem mass spectrometry (LC-MS/MS) system used 
in this work consisted of a Shimadzu (Columbia, MD, USA) Prominence UFLC unit with 
a controller (CBM-20A), two binary pumps (LC-20AD), an autosampler (SIL- 20AC), 
and an AB Sciex (Foster City, CA, USA) API 3200 turbo-ion-spray® triple quadrupole 
tandem mass spectrometer equipped with an electrospray ionization (ESI) probe. The LC- 
MS/MS system was controlled by AB Sciex Analyst® (version 1.5.1) software for its 
operation, data acquisition, and processing.
4.2.4.1 Tandem mass spectrometry
The triple quadrupole mass spectrometer was operated under negative 
electrospray ionization mode (ESI-) and tuned for compound-dependent and source- 
dependent parameters. The optimized compound-dependent parameters obtained by 
separate infusion of curcumin, COG, COS, curcumin-d6 and BPAG-d6 (5.00 μg mL-1) in 
the dilution solution by a syringe pump at a flow rate of 10.0 μL min-1 were shown in 
Table 4.1. The optimized source-dependent parameters obtained by flow injection 
analysis for curcumin, COG and COS were as follows: curtain gas at 30 psi; collision 
assisted dissociation gas at 6 psi; ionization voltage at -4500 V; source temperature at 400 
oC; sheath gas at 50 psi; desolvation gas at 55 psi; and resolution at 0.7 amu. Quantitation 
of analytes and the IS was done in multiple-reaction-monitoring (MRM) mode and the 
following mass transitions were used: curcumin at 367 > 149; COG at 543 > 217; COS at 
447 > 217; curcumin-d6 at 373 > 152; and BPAG-d6 at 409 > 233. The dwell time for
each transition was 35 ms.
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MS/MS parameters Curcumin COG COS Curcumin-d6 BPAG-d6
Declustering potential (DP, V) -45 -60 -40 -25 -90
Entrance potential (EP, V) -5.5 -4 -6 -4 -3
Collision energy (CE, eV) -25 -30 -29 -25 -35
Collision cell exit potential (CXP, V) -2.5 -2.5 -2.5 -2 -15
Table 4.1. The optimized compound-dependent MS/MS parameters.
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4.2.4.2 Liquid Chromatography
Analytical separation of curcumin, COG, and COS (analytes), and curcumin-d6 
and BPAG-d6 (internal standards, IS) was carried out at room temperature in gradient 
mode at a flow rate of 0.250 mL min-1 on a Waters (Milford, MA, USA) XTerra® MS 
C18 column (2.1 mm × 50 mm, 3.5 μm) connected to a Waters XTerra® MS C18 guard 
column (2.1 mm × 10 mm, 3.5 μm). The gradient elution program conducted using 10.0
mM ammonium formate (pH 3.0) (Solvent-A) and methanol (solvent B) at a flow rate of 
0.250 mL min-1 was as follows: 0-3.0 min (25-90%B), 3.0-7.50 min (90-90%B), 7.50­
7.51 min (90-25%B), 7.51-11.0 min (25-25%B). Methanol was used as the wash solvent 
between injections. For each analysis, 20.0 μL of the sample was injected into the system 
by the autosampler set at 4oC. The total run time was 11.0 min per sample and eluent of 
the first 2 min was diverted to waste. Prior to sample analysis, the column was 
equilibrated with mobile phase for at least 20 column volumes.
4.2.5 Clinical study
A phase II clinical study of curcumin in combination with vitamin D3 was 
conducted in previously untreated patients with early Stage Chronic Lymphocytic 
Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). A total number of 35 patients
were selected over the age of 18. In 28 day cycles, in cycle 1, the patients were given 8 
g/day of oral curcumin from day 1, followed by addition of 10,000 IU/day of oral vitamin 
D3 from day 8. Pharmaceutical grade curcumin 1.00 g tablets were provided by Sabinsa
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Corporation (East Windsor, NJ). Physical and laboratory assessments were conducted at 
three-time points, pretreatment (C1D1, cycle 1-day 1), prior to starting vitamin D3 (C1D8, 
cycle 1-day 8), and after treatment with both curcumin and vitamin D3 (C2D1, cycle 2- 
day 1) as specified in the CASE 5913 protocol [13]. Cycles 2-6 were planned in a similar 
manner. Plasma samples were extracted using the following procedure: About 4-5 ml of 
blood drawn into a labeled lithium heparinized tube (green-top) at each sampling time 
point and kept all sample tubes in an ice bath before centrifugation; centrifuged the blood 
samples at 1500 x g at 4 oC for 10 min; transferred the plasma into a labeled Nunc® 
CryoTube® vial; capped and mixed the sample tubes; and stored the sample tubes 
immediately at -70o C until LC-MS/MS analysis.
4.3 Results and discussion
4.3.1 Method development
4.3.1.1 Analytes
As several previous studies [14, 15, 19] indicated that COG and COS are the 
major metabolites of curcumin found in circulation and also in tissues after oral 
administration, these two metabolites along with curcumin were selected for the study. 
The LogP and pKa values calculated by the ACD/Labs® software version 11.02
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(Advanced Chemistry Development, Inc., Toronto, Ontario, Canada) were 3.07 and 8.11 
for curcumin, 0.25 and 2.78 for COG, and 1.91 and -4.23 for COS. The LogP values
indicated hydrophobic nature of these compounds, whereas varying pKa values suggested 
that these compounds dissociate at varying pH and pH plays a profound role in their 
chromatographic behavior. Based on these properties suitable solvents, mobile phase, and 
chromatographic column were selected for the analytical separation.
4.3.1.2 Internal standards (IS)
Usage of a heavy stable isotope of analyte as the IS is ideal due to their similar 
phyico-chemical properties and retention characteristics. For curcumin, its heavy stable 
isotope, curcumin-d6 was selected as an internal standard. For COG and COS, due to lack 
of commercially available heavy stable isotopes, initially curcumin-d6 was evaluated as 
the potential IS, however, during the sample preparation process it was noted that the 
curcumin was evaporated in minute quantities and being a heavy stable isotope of 
curcumin, curcumin-d6 was compensating the loss, which made it unsuitable for COG 
and COS. Structural analogs such as hesperetin and biochanin A (Sigma-Aldrich, St. 
Louis, MO, USA) were evaluated as the potential IS for COG and COS, but withdrawn 
due to matrix interferences and recovery issues. BPAG-d6 was chosen because it contains 
a glucuronide moiety as in COG, commercially available, and provided good quantitative 
data for both COG and COS. Curcumin-d6 for curcumin and BPAG-d6 for COG and COS 
were selected as the IS for subsequent work.
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4.3.1.3 Mass spectrometric detection
In this work, triple quadrupole tandem mass spectrometer was used for analyte 
detection. Curcumin and COG were detected in both positive and negative modes, 
however, COS was only detected in negative mode, therefore, negative electrospray 
ionization mode (ESI-) was chosen for identification and quantitation of analytes. As 
shown in Figure 4.2, analytes, curcumin, COG, and COS, and the IS, curcumin-d6 and 
BPAG-d6, readily produced deprotonated molecular ions [curcumin-H]-, [COG-H]-, and 
[COS-H]- at m/z 367, 543 and 447 and [curcumin-d6-H]-, and [BPAG- d6-H]- at m/z 373 
and 409 in methanol and ammonium formate solution (10.0 mM, pH 3.0) (1:1 v/v). These 
precursor ions were further fragmented in the collision cell into predominant product ions 
at m/z 149, 217, and 217 for curcumin, COG, and COS and 152 and 233 for curcumin-d6 
and BPAG-d6. Therefore, multiple reaction monitoring (MRM) mode was adopted for 
quantitation of analytes and the IS with the mass transitions of m/z 367 > 149 for 
curcumin, 543 > 217 for COG, 447 > 217 for COS, 373 > 152 for curcumin-d6, and 409 > 
233 for BPAG-d6.
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Figure 4.2. The mass spectra of precursor and product ions of curcumin, COG, COS, 
curcumin-d6, and BPAG-d6.
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4.3.1.4 Effect of pH on recoveries of curcumin, COG, and COS
Due to the analytes varying pKa values, the effects of pH on their recoveries were 
studied. In this study, a mixed standard solution containing curcumin, COG, and COS 
was spiked into pooled human blank plasma samples along with the mixed IS solution. 
Phosphate buffered saline (PBS) at pH 3.00, 3.10, 3.20, 3.30, 3.40, 3.50 and 4.00 was 
added and extracted using ethyl acetate. The organic layer was separated, dried under 
nitrogen flow and reconstituted with the dilution solution. The IS normalized intensities 
were presented in Figure 4.3. For COG, the intensity was reduced from pH 3.00 to 4.00, 
while for COS, it increased up to 3.40 and slightly reduced after that, and for curcumin, 
the intensity remained unchanged over the entire pH range. Based on the data, pH 3.00 
provides optimum separation for all the analytes and maintenance of pH 3.00 during 
sample preparation and mobile phase composition is beneficial for the analysis.
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Figure 4. 3. Effect of pH on recoveries of curcumin, COG, and COS.
128
4.3.1.5 Plasma sample preparation
For plasma sample preparation, liquid-liquid extraction (LLE) and protein 
precipitation (PPT) methods were tested. In LLE, PBS solution at pH 3.00 was used and 
followed the procedure described in section 3.1.4. PPT procedure was described in 
Section 4.2.3. For PPT, methanol and acetonitrile solvents were tested as protein 
precipitation solvents using 0.1% formic acid and 0.2M HCl to maintain the pH. Even 
though both of these solvents showed a similar response, ACN resulted in split peaks to 
some degree, so methanol was chosen for further study. Methanol with 0.1% formic acid 
in PPT resulted in higher response for all the analytes as compared to PBS at pH 3.00 in 
LLE. PPT was chosen as the method of choice because of its simplicity and relatively 
higher analyte response.
During plasma sample preparation, methanol extract containing analytes and the 
IS was dried under nitrogen gas flow, and the resultant residue was reconstituted in the 
dilution solution for the subsequent LC-MS/MS analysis. The initial mobile phase 
composition (methanol and ammonium formate (10.0 mM, pH 3.0) (1:3 v/v)) was tested 
as the dilution solution, however, it was replaced (methanol and ammonium formate 
(10.0 mM, pH 3.0) (1:1 v/v)) due to lower recovery of analytes and the IS in higher 
amount of aqueous solvent.
4.3.1.6 Liquid chromatographic separation
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Due to hydrophobic nature of curcumin, COG, COS, curcumin-d6, and BPAG-d6, 
the reversed-phase chromatographic column was considered for the analytical separation. 
Waters XTerra® MS C18 and Waters XTerra® MS C8 (Waters Corporation, Milford, MA, 
USA) columns were tested. Among them, Waters XTerra® MS C18 column was chosen 
because it exhibited more symmetrical peak shape and relatively higher signal response.
For the selection of an aqueous portion of the mobile phase, ammonium formate 
and ammonium acetate buffer solutions were tested at acidic and basic pH environment. 
Acidic pH resulted in higher signal response for the analytes in negative mode than in 
basic pH environment. This phenomenon may be due to the electrochemical reduction at
the capillary tip by the abundant protons in the solution and also their counterion's high
gas-phase proton affinities towards the analyte molecules [20]. Ammonium formate at pH 
3.0 was selected due to its higher signal intensity as compared to ammonium acetate.
For this work, the optimized liquid chromatographic separation was obtained 
using a Waters XTerra® MS C18 (2.1 mm × 50 mm, 3.5 μm) column and methanol and 
ammonium formate (10.0 mM, pH 3.0) in gradient elution mode at a flow rate of 0.250 
mL min-1. The total run time was 11.0 min with retention times of 3.93 min for BPAG-d6, 
4.50 min for COG, 4.69 min for COS, 5.08 min for curcumin, and 5.08 min for 
curcumin-d6 (Figure 4.4).
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Figure 4.4. The mass chromatograms of curcumin, COG, COS, curcumin-d6, and BPAG- 
d6 in human plasma (A) double blank plasma (with neither analyte nor the IS); (B) single 
blank plasma (with the IS only, curcumin-d6 at 25.0 ng mL-1 and BPAG-d6 at 100 ng mL- 
1); (C) curcumin, COG, and COS at 5.00 ng mL-1; (D) patient chromatograms of 
curcumin, COG, and COS at C2D1.
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4.3.2 Method validation
The LC-MS/MS method developed was validated according to the guidance set
forth by the US-FDA for industry on bioanalytical method validation [21].
4.3.2.1 Selectivity and Lower limit of quantitation
The selectivity of this method was evaluated by observing any interferents at the 
same retention times and mass transitions of the analyte and the IS in six individual blank 
plasma and pooled blank plasma matrices. As curcumin is an endogenous compound, 
very tiny peaks were observed at the retention times of curcumin and its metabolites; 
however, they were too small to measure quantitatively (Figure 4.4A). To prove the 
LLOQ of the method, the analytes were measured in six individual lots of blank human 
plasma matrices in five replicate measurements. The measured LLOQ for this method 
was 2.50 ng mL-1 for curcumin, COG, and COS. As shown in Table 4.2, the accuracy and
precisions were ≤ ± 8% and ≤ 11% for curcumin, ≤ ± 12% and ≤ 8% for COG, and ≤ ± 
11% and ≤ 9% for COS.
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Curcumin COG COS
Plasma
matrix
[Nominal] 
(ng mL-1)
[Measured] ± SD
(ng mL-1)
CV
(%)a
RE
(%)b
[Measured] ± SD
(ng mL-1)
CV
(%)a
RE
(%)b
[Measured] ± SD
(ng mL-1)
CV
(%)a
RE
(%)b
Lot 1 2.50 2.55 ± 0.28 11 2 2.20 ± 0.07 3 -12 2.23 ± 0.08 4 -11
Lot 2 2.50 2.31 ± 0.20 9 -8 2.66 ± 0.22 8 6 2.68 ± 0.18 7 7
Lot 3 2.50 2.64 ± 0.25 9 6 2.27 ± 0.11 5 -9 2.30 ± 0.07 3 -8
Lot 4 2.50 2.45 ± 0.12 5 -2 2.40 ± 0.13 5 -4 2.56 ± 0.24 9 3
Lot 5 2.50 2.61 ± 0.27 10 4 2.53 ± 0.21 8 1 2.56 ± 0.15 6 2
Lot 6 2.50 2.30 ± 0.04 2 -8 2.61 ± 0.17 7 4 2.70 ± 0.07 3 8
a %CV = (Standard deviation/mean) x 100%.
b %RE = [(measured - nominal)∕(nominal)] x 100%.
Table 4.2. Accuracy and precision of curcumin, COG, and COS at LLOQ in six individual lots of blank human plasma (n=5).
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4.3.2.2 Matrix factor and recovery
The absolute MF of curcumin, COG, and COS was determined by the mean peak 
area of the analyte at a specified concentration in the extracted plasma matrix over that of 
the analyte at the concentration in the dilution solution. The IS normalized MF was 
determined by the absolute MF of the analyte over that of the IS. Usage of heavy stable 
isotope as the internal standard limits the evaluation of MF to one lot of plasma instead of 
six individual plasma lots. Although, curcumin's heavy stable isotope was used for
curcumin, due to lack of commercially available stable isotopes for COG and COS and as 
a mixture of all the analytes was used throughout the analysis, we opted for evaluation of 
all the analytes in six individual plasma lots. In this study, curcumin, COG and COS QCs 
at three concentrations (7.5, 55.0 and 400 ng mL-1) were prepared in six individual lots of 
extracted blank plasma matrices. As shown in Table 4.3, the IS normalized MFs were
were 0.87-1.11 for curcumin, 0.91-1.07 for COG and 0.88-1.06 for COS. The data
indicated that the matrix effect could be corrected by the use of the IS in the
measurements of curcumin, COG, and COS.
The absolute recovery of curcumin, COG, and COS was determined by the mean 
peak area of the analyte at a specified concentration in plasma matrix over that of the 
analyte at the concentration in the extracted plasma matrix and multiplying by 100%. The 
IS normalized recovery was determined by the absolute recovery of the analyte over that 
of the IS and multiplying by 100%. In this study, curcumin, COG and COS QCs at three 
concentrations (7.5, 55.0 and 400 ng mL-1) were prepared in the pooled and the extracted 
pooled blank human plasma matrices. As shown in Table 4.4, the IS normalized
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recoveries were 94-102% for curcumin, 96-105% for COG, and 100-109% for COS. The 
data indicated that the extraction procedure used was efficient and consistent with the 
recovery of curcumin, COG, and COS for human plasma matrices.
135
Plasma
matrix
[Analyte]
(ng mL-1)
MFCurcumin
± SDa
MFIS 
± SDb
Curcumin
IS Normalized MF
± SDc
MFCOG
± SDa
MFis 
± SDb
COG
IS Normalized MF
± SDc
MFCOS
± SDa
MFis 
± SDb
COS
IS Normalized MF
± SDc
Lot 1 7.50 0.92±0.08 1.04±0.06 0.88±0.10 0.95±0.06 0.98±0.04 0.97±0.08 1.04±0.05 1.00±0.03 1.04±0.06
55.0 0.98±0.02 1.07±0.03 0.92±0.02 0.94±0.02 0.97±0.04 0.97±0.05 1.01±0.05 1.15±0.06 0.88±0.08
400 0.90±0.01 1.01±0.04 0.89±0.03 0.99±0.02 0.97±0.05 1.02±0.05 0.97±0.03 1.00±0.04 0.97±0.04
Lot 2 7.50 1.01±0.08 1.16±0.02 0.87±0.06 0.97±0.06 0.91±0.05 1.07±0.10 1.07±0.10 1.11±0.04 0.96±0.07
55.0 0.89±0.02 1.00±0.03 0.89±0.03 0.98±0.05 1.00±0.04 0.98±0.05 0.98±0.04 1.06±0.06 0.92±0.09
400 0.89±0.03 1.01±0.04 0.88±0.03 0.96±0.03 0.97±0.04 0.99±0.07 0.93±0.04 0.93±0.06 1.01±0.07
Lot 3 7.50 0.88±0.04 0.87±0.02 1.01±0.05 0.77±0.06 0.81±0.03 0.95±0.08 0.98±0.06 0.98±0.03 0.99±0.07
55.0 0.83±0.05 0.80±0.03 1.04±0.03 0.75±0.02 0.79±0.01 0.95±0.04 0.98±0.03 1.00±0.02 0.98±0.05
400 0.93±0.04 0.96±0.04 0.97±0.05 0.82±0.03 0.85±0.03 0.96±0.04 0.94±0.02 1.01±0.03 0.93±0.04
Lot 4 7.50 0.54±0.03 0.60±0.04 0.90±0.05 0.78±0.03 0.84±0.03 0.93±0.05 0.82±0.04 0.81±0.01 1.01±0.06
55.0 0.51±0.01 0.58±0.02 0.87±0.02 0.80±0.04 0.82±0.02 0.97±0.05 0.83±0.03 0.78±0.02 1.06±0.02
400 0.57±0.01 0.65±0.02 0.88±0.02 0.79±0.02 0.78±0.03 1.01±0.07 0.87±0.03 0.87±0.03 1.00±0.03
Lot 5 7.50 0.79±0.06 0.76±0.02 1.04±0.08 0.81±0.06 0.82±0.02 0.99±0.07 1.02±0.08 1.14±0.03 0.89±0.08
55.0 0.76±0.04 0.68±0.02 1.11±0.05 0.75±0.04 0.81±0.03 0.92±0.07 1.05±0.04 1.03±0.04 1.02±0.08
400 0.79±0.01 0.80±0.02 0.99±0.04 0.76±0.03 0.83±0.04 0.92±0.07 1.01±0.04 1.06±0.04 0.95±0.07
Lot 6 7.50 0.79±0.04 0.86±0.01 0.92±0.06 0.80±0.08 0.83±0.02 0.96±0.12 0.75±0.03 0.78±0.04 0.96±0.02
55.0 0.71±0.04 0.74±0.02 0.96±0.04 0.71±0.04 0.78±0.03 0.91±0.03 0.74±0.03 0.81±0.03 0.91±0.05
400 0.72±0.02 0.69±0.03 1.04±0.04 0.78±0.02 0.80±0.03 0.98±0.04 0.82±0.07 0.82±0.02 0.99±0.08
a MFAnalyte = (mean peak area of analyte in the extracted plasma matrix)/(mean peak area of analyte in the dilution solution). 
b MFIS = (mean peak area of the IS in the extracted plasma matrix)/(mean peak area of the IS in the dilution solution). 
c IS normalized MF = MFAnalyte/MFIS.
Table 4.3. Matrix factors of curcumin, COG, and COS QCs in six individual lots of blank human plasma (n = 5).
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Analyte [Analyte] 
(ng mL-1)
RecoveryAnalytea
± SD (%)
RecoveryISb
± SD (%)
IS Normalized
Recoveryc ± SD (%)
Curcumin 7.50 80 ± 4 81 ± 3 99 ± 7
55.0 78 ± 6 83 ± 4 94 ± 5
400 82 ± 2 80 ± 5 102 ± 6
COG 7.50 81 ± 3 81 ± 3 100 ±6
55.0 81 ± 1 84 ± 3 96 ± 2
400 86 ± 3 82 ± 3 105 ± 2
COS 7.50 88 ± 3 81 ± 2 109 ± 6
55.0 83 ± 2 83 ± 2 100 ± 4
400 87 ± 1 85 ± 3 102 ± 2
a RecoveryAnalyte = [(mean peak area of analyte in plasma matrix)/(mean peak area of analyte in extracted 
plasma matrix)] x100%.
b RecoveryIS = [(mean peak area of IS in plasma matrix)/(mean peak area of IS in extracted plasma matrix)] 
x 100%.
c IS normalized recovery = [(RecoveryAnalyte)/(RecoveryIS)] x 100%.
Table 4.4. Recovery of curcumin, COG, and COS in pooled blank human plasma (n = 5).
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4.3.2.3 Accuracy, precision, and dilution studies
Intra-assay accuracy and precision were determined by five replicate injections of 
extracted QC samples at three different concentrations (7.50, 55.0 and 400 ng mL-1). 
Inter-assay accuracy and precision were determined by five parallel injections of 
extracted plasma samples from five identical QCs at three different concentrations (7.50, 
55.0 and 400 ng mL-1) over three separate days. Dilution study was conducted at QC
 concentration of 1.25 x 103 ng mL-1, which was beyond the upper limit of the linear 
calibration curve (500 ng mL-1), and the analysis was carried out after 1:10 dilution using 
the pooled blank human plasma before the analysis.
As shown in Table 4.5, intra-assay accuracy and precision were ≤ ± 6% and ≤ 3% 
for curcumin, ≤ ± 8% and ≤ 8% for COG, and ≤ ± 8% and ≤ 9% for COS and inter-assay 
accuracy and precision were ≤ ± 8% and ≤ 9% for curcumin, ≤ ± 9% and ≤ 7% for COG,
and ≤ 13% and ≤ 4% for COS. The dilution studies showed that intra-assay accuracy and 
precision were ≤ 1% and ≤ 3% for curcumin, ≤ 4% and ≤ 6% for COG, and ≤ 1% and ≤ 
8% for COS and inter-assay accuracy and precision were ≤ ± 1% and ≤ 2% for curcumin,
≤ 1% and ≤ 2% for COG, and ≤ 2% and ≤ 5% for COS. The data indicated that the 
dilution of the plasma samples did not introduce errors into the quantitative measurement
of analytes.
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Intra-assaya Inter- bassayb
Analyte [Nominal](ng mL-1)
[Measured] ± SD 
(ng mL-1)
CV
(%)
RE
(%)
[Measured] ± SD 
(ng mL-1)
CV
(%)
RE
(%)
Curcumin 7.50 7.63 ± 0.20 3 2 7.66 ± 0.70 9 2
55.0 51.8 ± 1.2 2 -6 50.4 ± 2.0 4 -8
400 416 ± 14 3 4 427 ± 15 4 7
1.25 x 103c 1.26 x 103 ± 0.03 x 103 3 1 1.24 x 103 ± 0.02 x 103 2 -1
COG 7.50 7.41 ± 0.60 8 -1 7.14 ± 0.50 7 -5
55.0 50.7 ± 0.8 2 -8 50.5 ± 2.2 4 -8
400 420 ± 16 4 5 434 ± 16 4 9
1.25 x 103c 1.30 x 103 ± 0.08 x 103 6 4 1.26 x 103 ± 0.02 x 103 2 1
COS 7.50 7.39 ± 0.40 5 -1 7.79 ± 0.30 4 4
55.0 50.6 ± 4.6 9 -8 55.8 ± 1.2 2 1
400 415 ± 32 8 4 453 ± 13 3 13
1.25 x 103c 1.25 x 103 ± 0.10 x 103 8 1 1.28 x 103 ± 0.06 x 103 5 2
a Measured by five replicate measurements of each QC sample within a validation batch.
b Measured by five parallel measurements of five identical QC samples at each concentration over three validation batches.
c Dilution QC was measured after a 10-fold dilution with pooled blank human plasma and the reported concentration was back-calculated by multiplying 
a factor of 10.
Table 4.5. Intra- and inter-assay accuracy and precision of curcumin, COG, and COS in pooled blank human plasma (n = 5).
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4.3.2.4 Calibration curve
Calibration curves for curcumin, COG, and COS were constructed using one 
double-blank plasma (without analyte or the IS), one single-blank (with the IS only), and 
eight non-zero plasma calibrators (with analyte and the IS). The concentrations of non­
zero calibrators were 2.50, 5.00, 10.0, 25.0, 50.0, 125, 250 and 500 ng mL-1. The peak 
area ratios of analyte to the IS (y) were plotted against the concentrations of analyte 
plasma calibrators (x) with 1/x2 weighting. The calibration equations derived from three 
individual calibration curves from three validation batches were y = 0.0075(±0.0012) x + 
0.0031 (±0.003) for curcumin, y = 0.014(±0.0013) x + 0.0011 (±0.0012) for COG, and y 
= 0.019(±0.0032) x + 0.02 (±0.009) for COS with correlation coefficients of 0.999, 0.998
and 0.997 for curcumin, COG and COS, respectively (Figure 4.5). As shown in Table 4.6, 
the accuracy and precision of individual plasma calibrators were ≤ ± 3% and ≤ 6% for 
curcumin, ≤ ± 6% and ≤ 6% for COG, and ≤ ± 3% and ≤ 10% for COS.
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Figure 4.5. Calibration curve for curcumin, COG, and COS.
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Curcumin COG COS
[Nominal] 
(ng mL-1)
[Measured] ± SD 
(ng mL-1)
CV
(%)a
RE
(%)b
[Measured] ± SD 
(ng mL-1)
CV
(%)a
RE
(%)b
[Measured] ± SD 
(ng mL-1)
CV
(%)a
RE
(%)b
2.50 2.53 ± 0.06 2 1 2.52 ± 0.06 2 1 2.52 ± 0.10 4 1
5.00 4.98 ± 0.20 4 -1 5.08 ± 0.20 4 2 4.92 ± 0.40 8 -2
10.0 9.86 ± 0.50 5 -1 9.58 ± 0.40 4 -4 10.2 ± 0.5 5 2
25.0 24.2 ± 0.6 2 -3 23.5 ± 0.8 3 -6 24.2 ± 0.4 2 -3
50.0 50.3 ± 3.0 6 1 50.7 ± 3.0 6 1 49.6 ± 5.0 10 -1
125 127 ± 4 3 2 128 ± 6 5 2 125 ± 8 6 0
250 252 ± 8 3 1 254 ± 15 6 2 253 ± 21 8 1
500 508 ± 16 3 2 512 ± 18 4 2 508 ± 48 9 2
a %CV = (Standard deviation/mean) x 100%.
b %RE = [(measured - nominal)∕(nominal)] x 100%.
Table 4.6. Accuracy and precision of curcumin, COG, and COS plasma calibrators in three validation batches over three
different days (n=3).
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4.3.2.5 Stability
The stabilities of curcumin, COG, and COS in the test samples were determined 
by the measured mean-peak-area ratio of each analyte to its IS against freshly prepared
calibration curve of each analyte and expressed as percent recovery. In this work, the 
stock solution (1.00 mg mL-1) of analytes was kept on the bench top (23oC) for 6 and 24 
h before diluting to 10.0 and 50.0 ng mL-1. The QCs (7.50 and 400 ng mL-1) were kept on 
the bench top (23oC) before sample preparation and in an autosampler (4oC) after sample 
preparation for 6 and 24 h. The QCs were undergone three freeze-and-thaw cycles where 
the samples were frozen at -70oC for 24 h then thawed at room temperature (23oC) 
unassisted. The QCs were also kept at -70oC for two months to assess the long-term
storage effects.
The recoveries of curcumin, COG, and COS were summarized in Table 4.7. The
stock solutions were found to be stable on bench-top at room temperature for at least 24 h
prior to sample preparation with recoveries of 97-106% for curcumin, 104-108% for
COG, and 101-108% for COS. The plasma QCs were found to be stable at room
temperature for 6 hrs with recoveries of 98-100% for curcumin, 87-92% for COG, and
92-94% for COS, but unstable for 24 hrs with the exception of COS which showed
recovery of 94-95%. The plasma QCs were stable for 6 to 24 h in autosampler with
recoveries of 99-106% for curcumin, 97-105% for COG, and 87-107% for COS. The
recoveries of plasma QCs after three freeze-thaw cycles were 95-99% for curcumin, 97­
107% for COG, and 100-104% for COS. The long-term storage QC's had recoveries of
89-91% for curcumin, 93-95% for COG, and 89-105% for COS. These results indicated
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that there were no significant losses of curcumin, COG, and COS under the testing 
conditions with the exception of the storage at room temperature for more than 6 hrs.
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Test conditions Temperature (oC) Sample Recovery ± SD (%)
Curcumin COG COS
6 h 24 h 6 h 24 h 6 h 24 h
Bench-top 23 Stock solutiona 97 ± 4 97 ± 3 104 ± 2 105 ± 3 101 ± 5 103 ± 6
Stock solutionb 106 ± 7 103 ± 4 108 ± 7 108 ± 6 108 ± 4 101 ± 4
Bench-top 23 Low QCc 100 ± 1 65 ± 3 87 ± 4 68 ± 3 94 ± 4 95 ± 7
High QCc 98 ± 7 68 ± 7 92 ± 1 81 ± 7 92 ± 6 94 ± 3
Autosampler 4 Low QC 106 ±5 99 ± 5 97 ± 4 97 ± 5 87 ± 3 105 ± 8
High QC 101 ± 1 101 ± 8 104 ± 2 105 ± 4 93 ± 1 107 ± 1
Freeze-thaw cycles -70 to 23 Low QC 95 ± 4 97 ± 4 104 ± 5
High QC 99 ± 1 107 ± 3 100 ± 2
Long-term -70 Low QC 91 ± 3 93 ± 2 105 ± 5
High QC 89 ± 2 95 ± 3 89 ± 3
a The concentration of the stock solution was 1.00 mg mL-1, which was measured by serial dilution to 10.0 ng mL-1 in the dilution solution. 
b The concentration of the stock solution was 1.00 mg mL-1, which was measured by serial dilution to 50.0 ng mL-1 in the dilution solution. 
c The concentration of plasma low and high QCs were 7.50 ng mL-1 and 400 ng mL-1, respectively.
Table 4.7. Stability of curcumin, COG, and COS under various test conditions (n = 5).
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4.3.3 Clinical sample analysis
The developed method has been applied to the measurement of curcumin and 
metabolites in 35 patient's plasma samples. As shown in in Table 4.8, the pretreatment 
(C1D1) concentrations were < 2.50 ng mL-1 for curcumin, < 2.50 - 2.96 ng mL-1 for COG, 
and < 2.50 ng mL-1 for COS, the concentrations after 8 days (C1D8) were < 2.50 ng mL-1 
for curcumin, < 2.50 - 129 ng mL-1 for COG, and < 2.50 - 41.6 ng mL-1 for COS, and the 
concentrations after 28 days (C2D1) were < 2.50 ng mL-1 for curcumin, < 2.50 - 179 ng 
mL-1 for COG, and < 2.50 -53.1 ng mL-1 for COS. These data indicated that the orally 
ingested curcumin was rapidly converted into its metabolites through conjugation 
resulting in plasma concentrations of free curcumin lower than the LLOQ of the method, 
and COG was more predominant conjugate than COS. These results were consistent with 
those previously reported studies [7, 15].
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Curcumina 
(ng mL-1)
COGa
(ng mL-1)
COSa
(ng mL-1)
Sample C1D1 C1D8 C2D1 C1D1 C1D8 C2D1 C1D1 C1D8 C2D1
1 <LLOQ <LLOQ <LLOQ <LLOQ 13.5 16.3 <LLOQ 3.53 8.85
2 <LLOQ <LLOQ <LLOQ <LLOQ 120 75.3 <LLOQ 37.2 26.3
3 <LLOQ <LLOQ <LLOQ <LLOQ 14.0 10.1 <LLOQ <LLOQ 6.59
4 <LLOQ <LLOQ <LLOQ <LLOQ 21.7 56.7 <LLOQ 11.7 4.62
5 <LLOQ <LLOQ <LLOQ <LLOQ 16.6 17.3 <LLOQ <LLOQ <LLOQ
6 <LLOQ <LLOQ <LLOQ <LLOQ 39.5 8.69 <LLOQ 13.6 <LLOQ
7 <LLOQ <LLOQ NA <LLOQ 18.6 NA <LLOQ <LLOQ NA
8 <LLOQ <LLOQ NA <LLOQ 4.35 NA <LLOQ <LLOQ NA
9 <LLOQ <LLOQ <LLOQ <LLOQ 16.7 23.0 <LLOQ <LLOQ <LLOQ
10 <LLOQ <LLOQ <LLOQ <LLOQ 62.1 <LLOQ <LLOQ 12.3 <LLOQ
11 NA <LLOQ <LLOQ NA 11.8 65.7 NA <LLOQ 6.5
12 <LLOQ <LLOQ <LLOQ <LLOQ 40.2 77.1 <LLOQ 23.6 28.7
13 <LLOQ <LLOQ <LLOQ <LLOQ 102 179 <LLOQ 40.0 42.9
14 <LLOQ <LLOQ <LLOQ 2.96 70.7 110 <LLOQ 11.8 25.2
15 <LLOQ <LLOQ <LLOQ <LLOQ 18.3 16.1 <LLOQ <LLOQ <LLOQ
16 <LLOQ <LLOQ <LLOQ <LLOQ 46.2 42.7 <LLOQ 6.33 6.70
17 <LLOQ <LLOQ <LLOQ <LLOQ 24.3 19.8 <LLOQ 6.58 10.4
18 <LLOQ <LLOQ <LLOQ <LLOQ 61.9 44.9 <LLOQ <LLOQ 16.5
19 <LLOQ <LLOQ <LLOQ <LLOQ 19.0 15.6 <LLOQ 4.78 2.57
20 <LLOQ <LLOQ <LLOQ <LLOQ 42.6 36.7 <LLOQ 5.1 12.3
21 <LLOQ <LLOQ <LLOQ <LLOQ 39.4 65.4 <LLOQ 16.4 15.0
22 <LLOQ <LLOQ <LLOQ <LLOQ 129 60.1 <LLOQ 41.6 2.64
23 <LLOQ <LLOQ <LLOQ <LLOQ 86.8 155 <LLOQ 15.8 19.8
24 <LLOQ <LLOQ <LLOQ <LLOQ 21.9 109 <LLOQ 5.98 56.1
25 <LLOQ <LLOQ <LLOQ <LLOQ 93.3 73.8 <LLOQ 3.74 4.35
26 <LLOQ <LLOQ <LLOQ <LLOQ 9.63 6.99 <LLOQ <LLOQ <LLOQ
27 <LLOQ <LLOQ <LLOQ <LLOQ 5.26 11.2 <LLOQ <LLOQ <LLOQ
28 <LLOQ <LLOQ <LLOQ <LLOQ 25.7 5.87 <LLOQ 12.5 <LLOQ
29 <LLOQ <LLOQ <LLOQ <LLOQ 12.1 13.6 <LLOQ <LLOQ <LLOQ
30 <LLOQ <LLOQ <LLOQ <LLOQ 26.3 15.2 <LLOQ 6.72 5.46
31 <LLOQ <LLOQ <LLOQ <LLOQ 71.0 80.9 <LLOQ 36.0 53.1
32 <LLOQ <LLOQ <LLOQ <LLOQ 3.75 <LLOQ <LLOQ <LLOQ <LLOQ
33 <LLOQ <LLOQ <LLOQ <LLOQ 5.72 8.68 <LLOQ <LLOQ 3.14
34 <LLOQ <LLOQ <LLOQ <LLOQ 48.4 71.8 <LLOQ 19.7 18.2
35 NA <LLOQ NA NA <LLOQ NA NA <LLOQ NA
a LLOQ of curcumin, COG, and COS was 2.5 ng mL-1 
a NA denotes samples were not available
Table 4.8. Measured concentrations of curcumin, COG, and COS in patient samples.
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4.4 Conclusion
An LC-MS/MS method for the quantitative determination of curcumin and its
metabolites, curcumin glucuronide, and curcumin sulfate, in human plasma has been
developed and validated. In this method, curcumin, COG, and COS and the IS were 
extracted from human plasma by protein precipitation and separated on Waters XTerra® 
MS C18 column with gradient elution conditions. Quantitation of curcumin, COG, and
COS was carried out by negative electrospray ionization tandem mass spectrometry 
operated in MRM mode. The method developed was successfully applied to the 
measurement of curcumin and its metabolites in human plasma samples in a phase II
clinical trial.
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